Synthesis of substituted methylenepyrimidobenzothiazolones as potential cytotoxic agents

Jakub Modranka,^a Anna Pietrzak^b, Wojciech M. Wolf^b and Tomasz Janecki^{a*}

^aInstitute of Organic Chemistry, Lodz University of Technology, Żeromskiego 116, 90-924 Łódź, Poland

^bInstitute of General and Ecological Chemistry, Lodz University of Technology, Żeromskiego 116, 90-924 Łódź, Poland

E-mail: tomasz.janecki@p.lodz.pl

Dedicated to Prof. Jacek Młochowski on the occasion of his 80th birthday

Received 05-23-2016

Accepted 07-14-2016

Published on line 08-23-2016

Abstract

A range of biologically important substituted 3-methylidene-2,3-dihydro-4*H*-pyrimido[2,1-*b*][1,3]benzothiazol-4-ones and 3-methylidene-3,4-dihydro-2*H*-pyrimido[2,1-*b*][1,3]benzothiazol-2-ones was synthesized applying Horner-Wadsworth-Emmons methodology for the introduction of *exo*-methylidene bond onto a heterocyclic ring. Crucial in this approach, phosphonates were prepared by the reaction of ethyl 2-diethoxyphosphoryl-3-methoxyacrylate or ethyl 2-diethoxyphosphoryl-3-chloroacrylate with 2-aminobenzothiazoles, followed by addition of Grignard reagents to the obtained 3-diethoxyphosphoryl-4*H*-pyrimidobenzothiazol-4-ones or 3-diethoxyphosphoryl-2*H*-pyrimido[2,1-*b*][1,3]benzothiazol-2-ones, respectively. Surprising, ambident behavior of 2-aminobenzothiazoles towards ethyl 2-diethoxyphosphoryl-3-methoxyacrylate and ethyl 2-diethoxyphosphoryl-3-chloroacrylate is also discussed.

Keywords: Pyrimidobenzothiazolones, methylenepyrimidobenzothiazolones, Michael addition, Horner-Wadsworth-Emmons olefination, phosphorylated azaheterocycles

Introduction

Fused polyheterocycles, especially those containing nitrogen atoms, represent the core structural motif of a wide range of biologically active compounds.¹ Not surprisingly, they are an important field of research and a very attractive target for the drug industry. One of such characteristic structural motifs are pyrimidobenzothiazolones, in which a pyrimidine ring is fused with another pharmacophorically active nucleus, benzothiazole, through a nitrogen atom. Synthesis and biological activity of both possible structural arrangements, 4*H*-pyrimido[2,1-*b*][1,3]benzothiazol-4-ones **1** and 2*H*-pyrimido[2,1-*b*][1,3]benzothiazol-2-ones **2** has been reported (Figure 1).

Figure 1. Structures of 4*H*-pyrimido[2,1-*b*][1,3]benzothiazol-4-ones **1** and 2*H*-pyrimido[2,1-*b*][1,3]benzothiazol-2-ones **2**.

Pyrimidobenzothiazol-4-ones **1** substituted at positions 2, 3 or in benzothiazole moiety were synthesized by condensation of 2-aminobenzothiazoles with diethyl malonates² or ethyl acetoacetate^{3,4} or in the reaction of 2-aminobenzothiazoles with various Michael acceptors, such as diethyl alkoxymethylidenemalonates,⁵⁻⁸ ethyl 2-cyano-3,3-bismethylthioacrylate,^{9,10} 2-cyano-3-dimethylaminoacrylohydrazides¹¹ or dimethyl aminofumarate.⁶ Pyrimidobenzothiazol-4-ones **1** display interesting biological properties, for example anticancer,⁹⁻¹¹ antimicrobial,^{2,4,9} antiallergic⁶ or antifungal.^{3,4} Syntheses of 2*H*-pyrimido[2,1-*b*][1,3]benzothiazol-2-ones **2** are usually less effective and were accomplished in a three-component reaction of a substituted benzaldehyde, malonate and 2-aminobenzothiazole¹² or by heating 2-aminobenzothiazoles with propargylic acids,¹³ but-2-yn-1,4-diates^{14,15} or ethyl cyanoacetate.¹⁶ Another method is a microwave-promoted reaction of 2-aminobenzothiazoles with Baylis-Hillman acetates.¹⁷ Biological activity of 2*H*-pyrimido[2,1-*b*][1,3]benzothiazol-2-ones **2** is poorly recognized. It was reported that 4-imino-3-aryldiazenyl-3,4-dihydro-2*H*-pyrimido[2,1-*b*][1,3]benzothiazol-2-ones displayed antibacterial activity¹⁶ and several *N*'-substituted-4-carbohydrazide-3,4-dihydro-2*H*-pyrimido[2,1-*b*][1,3]benzothiazol-2-ones have cytotoxic activity against kidney, lung, colon, prostate or breast cancer cell lines.^{14,15}

Continuing our search for new heterocyclic frameworks with anticancer activity we decided to modify the structure of pyrimidobenzothiazolones by introducing *exo*-methylidene bond α to a carbonyl group. We assumed that such a modification might enhance the cytotoxic activity of the target methylidenepyrimidobenzothiazolones. Our reasoning was based on a well-established structure-activity relationship linking the strong cytotoxic activity displayed by a large group of natural and synthetic α -alkylidenelactones and lactams with the presence of *exo*-alkylidene bond conjugated with a carbonyl group.^{18,19} In this paper we present the synthesis of 3-methylidene-2,3-dihydro-4*H*-pyrimido[2,1-*b*][1,3]benzothiazol-4-ones **11** and 3-methylidene-3,4-dihydro-2*H*-pyrimido[2,1-*b*][1,3]benzothiazol-2-ones **13**

using, well-recognized in our laboratory, Horner-Wadsworth-Emmons methodology for the introduction of the *exo*-methylidene double bond onto a heterocyclic ring.²⁰

Results and Discussion

Following the success of our recent studies involving a new methodology which can be applied to the synthesis of diverse phosphorylated *ortho*-fused azaheterocycles²¹ we decided to further test the efficiency of 2-diethoxyphosphoryl-3-methoxyacrylate **4** in the preparation of 3-diethoxyphosphoryl-4*H*-pyrimido[2,1-*b*][1,3]benzothiazol-4-ones **6**, which are crucial intermediates in the present synthesis. To our delight, reacting methoxyacrylate **4** with 2-aminobenzothiazoles **3a-d** in methanol at room temperature for 24 hours followed by the evaporation of methanol from the reaction mixture gave crude aminoacrylates **5a-d** which were formed as mixtures of *E* and *Z* isomers. Their spectral data were in accordance with their structure. For example, in the ³¹P NMR spectrum of crude **5a** only two signals from *E* and *Z* isomers were present (δ 20.10 and 21.26 in 35/65 ratio, respectively). To simplify the procedure, crude aminoacrylates **5a-d** were used in the next step. Heating them in Dowtherm A at 250 °C for 30 minutes induced intramolecular cyclization and, after column chromatography, pure 3-diethoxyphosphorylpyrimidobenzothiazol-4-ones **6a-d** were obtained in moderate to good yields (Scheme 1, Table 1). ¹H, ¹³C and ³¹P NMR spectra of **6a-d** were in full agreement with their structures.

Scheme 1. Synthesis of 3-diethoxyphosphoryl-4*H*-pyrimidobenzothiazol-4-ones **6a-d**. Reaction conditions: 1) methanol, 24 h, rt; 2) Dowtherm A, 30 min., 250 °C.

Looking for milder reaction conditions for the synthesis of **6**, we decided to test the reaction of 2-aminobenzothiazoles **3a,b,e** with 2-diethoxyphosphoryl-3-chloroacrylate **7**. Chloroacrylate **7** has not been reported so far but turned out to be easily available by SOCl₂ chlorination of ethyl 2-diethoxyphosphoryl-3-hydroxyacrylate (see Experimental). Surprisingly, the reaction of **7** with 2-aminobenzothiazoles **3a,b,e** in THF, in the presence of pyridine proceeded smoothly at room temperature giving products isomeric to **6** - 3-diethoxyphosphoryl-2*H*-pyrimido[2,1-*b*][1,3]benzothiazol-2-ones **9a,b,e**, in good yields (Scheme 2, Table 1). In this reaction we were unable to isolate the intermediate substitution products **8a,b,e**. The NMR spectra of **9a,b,e** were in accordance with their structures. Furthermore, the two regioisomers **6a** and **9a** were selected for X-ray single crystal analysis to explicitly confirm their structures. The crystal structure of **9a** is reported herein. Crystal data for **6a** have been already deposited in the Cambridge Structural Database²² by us as part of a publication on new crystal packing motifs. Views of molecules **6a** and **9a** as determined in the crystalline state are presented in Figure 2. Surprisingly, conformation around the exocyclic P1-C1 bond differs significantly in these two regioisomers. It can be conveniently defined by the O4-P1-C1-C10 torsion angle which adopts values -176.20(13)° (*anti*) and -65.23(13)° (*gauche*) in **6a** and **9a**, respectively. The *gauche*

conformation as in **9a** is additionally stabilized by the hydrogen bond between a phosphoryl oxygen atom and the water molecule which was localized in the crystal.

Scheme 2. Synthesis of 3-diethoxyphosphoryl-2H-pyrimido[2,1-*b*][1,3]benzothiazol-2-ones **9a,b,e**. Reaction conditions: THF, pyridine, 24 h, rt.

Table 1. 3-Diethoxyphosphoryl-4H-pyrimido[2,1-*b*][1,3]benzothiazol-4-ones **6a-d** and 3-diethoxyphosphoryl-2H-pyrimido[2,1-*b*][1,3]benzothiazol-2-ones **9a,b,e** obtained

Compound	R ¹	6	9
		Yield (%) ^a	Yield (%) ^a
a	H	89	96
b	Me	48	58
c	Cl	63	-
d	NO ₂	71	-
e	OMe	-	76

^a Yield of isolated, purified product, based on **3**.

The unexpected formation of pyrimidobenzothiazol-2-ones **9** can be rationalized assuming that the addition of 2-aminobenzothiazoles **3** to chloroacrylate **7** proceeds via the imine nitrogen atom and, after the elimination of chloride, substitution products **8** are formed, which undergo spontaneous intramolecular cyclization to yield **9**. It is worth mentioning, that previously reported additions of 2-aminobenzothiazoles to 2-alkoxyalkylidenemalonates⁵⁻⁸ or ethyl 2-cyano-3,3-bis(methylthio)acrylate^{9,10} proceeded always via the amine nitrogen, yielding 3-alkoxycarbonyl or 3-cyanopyrimidobenzothiazol-4-ones, respectively. In turn, addition of 2-aminobenzothiazole **3a** to alkyl 2-arylidene malonates proceeds via the imine nitrogen atom.¹² Reactions of 2-aminobenzothiazoles with 2-chloromethylidenemalonates have not been reported. To shed more light on the observed phenomenon, we performed the reaction of 2-diethoxyphosphoryl-3-methoxyacrylate **4** with 2-aminobenzothiazole **3a** in THF, in the presence of pyridine and it turned out that the substitution product **5a** was formed exclusively. Therefore the different regioselectivity noticed for the substrates **4** and **7** is caused by the different substrate structure rather than the different reaction conditions. However, full understanding of our observation certainly needs further investigation. Nevertheless, the fully regioselective, ambident reactivity of 2-aminobenzothiazoles **3** towards **4** and **7** gives obvious synthetic advantages and the potential of this phenomenon is currently being tested in our laboratory.

Figure 2. A view of molecules **6a** and **9a** (hydrogen labels and disordered water molecule as in **9a** are omitted for clarity). Displacement ellipsoids are drawn at the 50% probability level. Selected geometric parameters; **6a**: P1-C1 1.7813(16)Å, C3-S1-C4 90.35(8)°, O4-P1-C1 112.99(7)°, C3-N1-C2 115.07(14)°, C3-N2-C10 121.11(13)°, C2-C1-C10 121.08(14)°, O4-P1-C1-C10 -176.20(13)°; **9a**: P1-C1 1.7801(15)Å, C9-S1-C8 90.62(7)°, O4-P1-C1 114.39(7)°, C9-N1-C10 118.35(13)°, C2-C1-C10 120.17(14)°, C2-N2-C9 118.77(13)°, O4-P1-C1-C10 -65.23(13)°.

The synthesised 3-diethoxyphosphorylpyrimidobenzothiazol-4-ones **6a-d** and 3-diethoxyphosphorylpyrimidobenzothiazol-2-ones **9a,b,e** were next used as Michael acceptors in reactions with various Grignard reagents. Additions took place effectively in the presence of CuI and after a standard work-up and purification by column chromatography, 2-substituted 3-diethoxyphosphoryl-2,3-dihydro-4H-pyrimido[2,1-*b*][1,3]benzothiazol-4-ones **10a,d,e,i-l** and 3-diethoxyphosphoryl-3,4-dihydro-2H-pyrimido[2,1-*b*][1,3]benzothiazol-2-ones **12a-j,m** were obtained in good to excellent yields (Scheme 3, Table 2). Only additions to benzothiazol-4-one **6d** were ineffective and always gave a complex mixture of products. Benzothiazol-4-ones **10e,j,l** substituted with a phenyl group were obtained as single *trans* isomers and benzothiazol-4-ones **10a,d,i,k** as a mixture of *trans* and *cis* isomers in a ratio given in Table 2. In turn, benzothiazol-2-ones **12a-j,m** were all formed as single *trans* isomers. Formation of *trans*-benzothiazolones **10** and **12** as major or single stereoisomers is in accordance with a well-established observation, that in this type of Michael addition, thermodynamic control is usually observed.^{23,24} Analysis of ¹H, ¹³C and ³¹P NMR spectra fully confirmed the structures of benzothiazolones **10** and **12** and their stereochemistry. Diagnostic for a *trans* diaxial arrangement of diethoxyphosphoryl group and R² substituent were coupling constants ³J_{H3-H2} = 0.9-1.2 Hz in *trans*-benzothiazol-4-ones **10** and ³J_{H3-H4} = 0.0-0.8 Hz in *trans*-benzothiazol-2-ones **12**. Corresponding coupling constants ³J_{H3-H2} for *cis*-benzothiazol-4-ones **10a,d,i,k** were in the range of 5.5-5.7 Hz. Also, coupling constants ³J_{R2-P} in all *trans*-benzothiazolones **10** and **12** were in the range of 17.0-18.7 Hz. Unfortunately, we were unable to determine the ³J_{R2-P} coupling constants from ¹³C NMR spectra of *cis*-benzothiazol-4-ones **10a,d,i,k**, due to small amount of these isomers in the mixture. These data are in full agreement with the corresponding coupling constants observed for *trans*-4-alkyl-3-diethoxyphosphorylchroman-2-ones with a diaxial arrangement of alkyl and diethoxyphosphoryl group.^{25,26}

In the final step of our synthesis, pyrimidobenzothiazolones **10** and **12** were employed in Horner-Wadsworth-Emmons olefinations with formaldehyde. Reaction of pyrimidobenzothiazol-4-ones **10a,d,e,i-l** with an excess of paraformaldehyde proceeded smoothly in the presence of NaH as a base. Crude 3-methylidene-2,3-dihydro-4*H*-pyrimido[2,1-*b*][1,3]benzothiazol-4-ones **11a,d,e,i,j** were purified by column chromatography to give the target compounds in good to moderate yields (Scheme 3, Table 2). Disappointingly, methylidenepyrimidobenzothiazolones **11k,l** were very unstable and decomposed during attempted purification by column chromatography. Decomposition was noticeable also during the storage of the crude compounds in a refrigerator for several hours. The ^1H NMR spectra of **11k,l** given in the experimental section were therefore registered immediately after the reaction, using crude products. Slow decomposition was also observed for the remaining methylidenepyrimidobenzothiazolones **11**, even if they were kept in the refrigerator.

Scheme 3. Synthesis of methylidenepyrimidobenzothiazolones **11a,d,e,i-l** and **13a-j,m**. Reaction conditions: (a) R^2MgCl , cat. CuI, THF, -78°C to rt; b) NaH, $(\text{CH}_2\text{O})_n$, THF, rt, 4 h; c) R^2MgCl , THF, 0°C to rt; d) K_2CO_2 , $(\text{CH}_2\text{O})_n$, THF, rt, 24 h.

Table 2. Substituted 3-diethoxyphosphorylpyrimidobenzothiazolones **10a,d,e,i-l** and **12a-j,m** and methylidenepyrimidobenzothiazolones **11a,d,e,i-l** and **13a-j,m** obtained

Compound	R^1	R^2	10		11 Yield ^b (%)	12 Yield ^b (%)	13 Yield ^b (%)
			<i>trans/cis</i> ratio ^a	Yield ^b (%)			
a	H	Me	88/12	80	51	73	76
b	H	Et	-	-	-	68	82
c	H	<i>i</i> -Pr	-	-	-	43	32
d	H	<i>n</i> -Bu	94/6	75	34	72	87
e	H	Ph	>99/1	93	69	68	61
f	Me	Me	-	-	-	71	82
g	Me	Et	-	-	-	85	84
h	Me	<i>i</i> -Pr	-	-	-	78	39

Table 2. Continued

Compound	R ¹	R ²	10		11	12	13
			<i>trans/cis</i> ratio ^a	Yield ^b (%)	Yield ^b (%)	Yield ^b (%)	Yield ^b (%)
i	Me	<i>n</i> -Bu	93/7	79	76	74	87
j	Me	Ph	>99/1	83	52	79	71
k	Cl	<i>n</i> -Bu	94/6	95	- ^c	-	-
l	Cl	Ph	>99/1	85	- ^c	-	-
m	OMe	<i>n</i> -Bu	-	-	-	89	76

^a Ratio determined from ³¹P NMR spectra of the crude compounds.

^b Yield of isolated, purified product, based on **6**, **10**, **9** or **12**, respectively.

^c Yield was not determined due to fast decomposition of the obtained compounds.

In turn, synthesis of 3-methylidene-3,4-dihydro-2*H*-pyrimido[2,1-*b*][1,3]benzothiazol-2-ones **13a-j,m** was accomplished when pyrimidobenzothiazol-2-ones **12a-j,m** were treated with paraformaldehyde in the presence of K₂CO₃ as a base. Purification of the crude products by column chromatography gave methylidenepyrimidobenzothiazolones **13a-j,m** in good to moderate yields (Scheme 3, Table 2). In contrast to the methylidenepyrimidobenzothiazol-4-ones **11**, methylidenepyrimidobenzothiazol-2-ones **13** were stable at room temperature for at least several weeks.

In conclusion, we have performed an efficient synthesis of new, biologically important methylidenepyrimidobenzothiazolones **11** and **13** using Horner-Wadsworth-Emmons methodology. It is worth stressing that key intermediates **6** and **9** were effectively obtained due to the unexpected discovery of the ambient and fully regioselective behavior of 2-aminobenzothiazoles **3** toward methoxyacrylate **4** and chloroacrylate **7**. The structure of both regioisomers **6a** and **9a** were unequivocally determined by X-ray structure analysis. Currently, target methylidenepyrimidobenzothiazolones **13** are being assessed for their cytotoxicity and preliminary tests show that they are highly active. These, very interesting biological results will be published shortly.

Experimental Section

General. NMR spectra were recorded on a Bruker DPX 250 or Bruker Avance II instrument at 250.13 MHz or 700 MHz for ¹H, 62.9 MHz or 176 MHz for ¹³C, and 101.3 MHz or 283 MHz for ³¹P NMR using tetramethylsilane as internal and 85% H₃PO₄ as external standard. ³¹P NMR spectra were recorded using broadband proton decoupling. IR spectra were recorded on a Bruker Alpha ATR spectrophotometer. Melting points were determined in open capillaries and are uncorrected. Column chromatography was performed on Aldrich® silica gel 60 (230-400 mesh). Thin-layer chromatography was performed with precoated TLC sheets of silica gel 60 F₂₅₄ (Aldrich®). The purity of tested compounds was determined by combustion elemental analyses (CHN, elemental analyzer EuroVector 3018, Elementar Analysensysteme GmbH). Reagents and starting materials were purchased from commercial vendors and used without further purification. All organic solvents were dried over appropriate drying agents and distilled prior to use. Standard syringe techniques were used for transferring dry solvents. The crystal data were collected on a Bruker Smart APEX2 diffractometer at 100 K

using Incoatec $\mu\text{S Cu-K}\alpha$ ($\lambda = 1.54178 \text{ \AA}$) as a source of radiation. Data reduction and structure solution was performed with the Bruker APEX2 Suite of programs.²⁷ The ShelXle/XL were further applied for structure refinement and visualization. The CCDC Mercury and Mogul²⁸ programs were used for molecular geometry and crystal packing examinations.

Ethyl 3-chloro-2-(diethoxyphosphoryl)acrylate (7). To a mixture of triethyl phosphonoacetate (10.5 mL, 52 mmol) and ethyl formate (14.1 mL, 170 mmol) in EtOH (20 mL) NaOEt in EtOH (15%, 100 mmol) was added. The reaction was stirred at ambient temperature for 3 d. The mixture was concentrated in *vacuo*, CH_2Cl_2 (100 mL) was added, and the mixture was acidified to pH ca. 1.5 with 10% aq HCl solution. The organic layer was separated, dried over Na_2SO_4 and concentrated under reduced pressure. The crude ethyl 2-(diethoxyphosphoryl)-3-hydroxyacrylate was dissolved in toluene (75 mL), then SOCl_2 (4 mL, 55 mmol) followed by catalytic amount of DMF (0.1 mL) were added. The mixture was heated under reflux for 4 h. The solvent was evaporated, and the crude product was distilled under reduced pressure to afford pale yellow product **7** (87%, bp 100-110 °C/0.4 mbar) as a mixture of two isomers *E/Z* = 20/1. IR $\nu(\text{cm}^{-1})$: 2984 (w), 1727 (m), 1211 (s), 1011 (vs), 974 (vs); ^1H NMR (250 MHz, CDCl_3) δ 7.80 (d, *J* 35.0 Hz, 1H, minor, *H*-3), 7.41 (d, *J* 14.4 Hz, 1H, major, *H*-3), 4.32 (q, *J* 7.1 Hz, 2H, major and minor, $\text{CH}_3\text{CH}_2\text{OC}(\text{O})$), 4.07 – 4.26 (m, 4H, major and minor, $(\text{CH}_3\text{CH}_2\text{O})_2\text{P}(\text{O})$), 1.30-1.36 (m, 9H, major and minor, $\text{CH}_3\text{CH}_2\text{OC}(\text{O})$, $(\text{CH}_3\text{CH}_2\text{O})_2\text{P}(\text{O})$); ^{13}C NMR (63 MHz, CDCl_3 , major) δ 162.5 (d, *J* 9.7 Hz, C-1), 140.3 (d, *J* 18.1 Hz, C-3), 128.6 (d, *J* 175.4 Hz, C-2), 63.2 (d, *J* 5.4 Hz, $\text{CH}_3\text{CH}_2\text{OP}(\text{O})$), 61.9 (s, $\text{CH}_3\text{CH}_2\text{OC}(\text{O})$), 16.2 (d, *J* 6.6 Hz, $(\text{CH}_3\text{CH}_2\text{O})_2\text{P}(\text{O})$), 14.0 (s, $\text{CH}_3\text{CH}_2\text{OC}(\text{O})$); ^{31}P NMR (101 MHz, CDCl_3) δ 9,60 (major), 7,96 (minor). Anal. Calcd for $\text{C}_9\text{H}_{16}\text{ClO}_5\text{P}$ (270.65): C, 39.94; H, 5.94%. Found: C, 39.87; H, 5.98%.

General procedure for the synthesis of diethyl (4-oxo-4*H*-benzothiazolopyrimidin-3-yl)phosphonates 6a-c,e.

To a solution of 2-aminobenzotriazole **3a-c,e** (10.0 mmol) in MeOH (50 mL) 2-diethoxyphosphoryl-3-methoxyacrylate (**4**) (2.66 g, 10.0 mmol) was added and the mixture was stirred for 24 h. Next, the MeOH was evaporated and Dowtherm A (150 mL) was added. The mixture was heated under reflux for 30 minutes. After cooling, the reaction mixture was applied to a silica gel column. The column was washed in turn with hexane (150 mL), EtOAc (150 mL) and EtOH (150 mL). The EtOH fraction was evaporated and the residue purified by column chromatography (eluent: EtOAc–MeOH, 10:1).

Diethyl (4-oxo-4*H*-benzo[4,5]thiazolo[3,2-*a*]pyrimidin-3-yl)phosphonate (6a). (89%); yellow crystals; mp 70-73 °C; IR $\nu(\text{cm}^{-1})$: 2978 (w), 1691 (m), 1486 (s), 1243 (s), 1013 (vs), 956 (vs); ^1H NMR (700 MHz, CDCl_3) δ 9.18 – 9.10 (m, 1H, *H*-Ar), 8.57 (d, *J* 9.6 Hz, 1H, *H*-2), 7.79 – 7.71 (m, 1H, *H*-Ar), 7.62 – 7.51 (m, 2H, *H*-Ar), 4.38 – 4.15 (m, 4H, CH_2OP), 1.39 (t, *J* 7.0 Hz, 6H, $\text{CH}_3\text{CH}_2\text{O}$); ^{13}C NMR (176 MHz, CDCl_3) δ 166.5 (s, C-Ar), 159.3 (d, *J* 9.5 Hz, C-3), 158.9 (d, *J* 12.7 Hz, C(O)), 135.7 (s, C-Ar), 127.7 (s, CH-Ar), 127.5 (s, CH-Ar), 124.1 (s, C-Ar), 121.9 (s, CH-Ar), 120.4 (s, CH-Ar), 108.8 (d, *J* 197.7 Hz, C-2), 62.8 (d, *J* 3.1 Hz, CH_2OP), 62.8 (d, *J* 4.2 Hz, CH_2OP), 16.4 (d, *J* 6.3 Hz, $\text{CH}_3\text{CH}_2\text{OP}$); ^{31}P NMR (283 MHz, CDCl_3) δ 13.91. Anal. Calcd for $\text{C}_{14}\text{H}_{15}\text{N}_2\text{O}_4\text{PS}$ (338.32): C, 49.70; H, 4.47; N 8.28%. Found: C, 49.59; H, 4.50; N 8.26% CCDC 1478184 contains the crystallographic data of **6a**. These data can be obtained free of charge from The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif.

Diethyl (8-methyl-4-oxo-4*H*-benzo[4,5]thiazolo[3,2-*a*]pyrimidin-3-yl)phosphonate (6b). (48%); yellow crystals; mp 115-118 °C, IR $\nu(\text{cm}^{-1})$: 2978 (w), 1687 (m), 1486 (s), 1219 (s), 1013 (vs); ^1H NMR (250 MHz, CDCl_3) δ 8.97 (d, *J* 8.7 Hz, 1H, *H*-Ar), 8.53 (d, *J* 9.6 Hz, 1H, *H*-2), 7.53 (d, *J* 1.4 Hz, 1H, *H*-Ar), 7.37 (dd, *J* 8.7, 1.4 Hz, 1H, *H*-Ar), 4.40 – 4.15 (m, 4H, CH_2OP), 2.50 (s, 3H, CH_3), 1.23 (t, *J* 7.0 Hz, 6H, $\text{CH}_3\text{CH}_2\text{O}$); ^{13}C NMR (63 MHz, CDCl_3) δ

166.3 (s, C-Ar), 159.1 (d, J 11.3 Hz, C-3), 158.7 (d, J 12.7 Hz, C(O)), 138.1 (s, C-Ar), 133.4 (s, C-Ar), 128.5 (s, CH-Ar), 124.0 (s, C-Ar), 121.7 (s, CH-Ar), 120.0 (s, CH-Ar), 108.4 (d, J 197.6 Hz, C-2), 62.7 (d, J 5.8 Hz, CH₂OP), 21.3 (s, CH₃), 16.3 (d, J 6.4 Hz, CH₃CH₂OP); ³¹P NMR (101 MHz, CDCl₃) δ 14.94. Anal. Calcd for C₁₅H₁₇N₂O₄PS (352.34): C, 51.13; H, 4.86; N 7.95%. Found: C, 51.00; H, 4.85; N 7.99%.

Diethyl (8-chloro-4-oxo-4H-benzo[4,5]thiazolo[3,2-*a*]pyrimidin-3-yl)phosphonate (6c). (63%); yellow crystals; mp 145-147 °C, IR ν (cm⁻¹): 2981 (w), 1690 (m), 1485 (s), 1250 (s), 1026 (vs); ¹H NMR (700 MHz, CDCl₃) δ 9.07 (d, J 9.0 Hz, 1H, *H*-Ar), 8.56 (d, J 9.6 Hz, 1H, *H*-2), 7.74 (d, J 2.1 Hz, 1H, *H*-Ar), 7.55 (dd, J 9.0, 2.1 Hz, 1H, *H*-Ar), 4.34 – 4.22 (m, 4H, CH₂OP), 1.39 (t, J 7.1 Hz, 6H, CH₃CH₂O); ¹³C NMR (176 MHz, CDCl₃) δ 166.0 (s, C-Ar), 159.3 (d, J 11.3 Hz, C-3), 158.7 (d, J 12.7 Hz, C(O)), 134.2 (s, C-Cl), 133.5 (s, C-Ar), 127.9 (s, CH-Ar), 125.7 (s, CH-Ar), 121.8 (s, C-Ar), 121.2 (s, CH-Ar), 109.3 (d, J 197.3 Hz, C-2), 62.9 (d, J 5.7 Hz, CH₂OP), 16.4 (d, J 6.3 Hz, CH₃CH₂OP); ³¹P NMR (283 MHz, CDCl₃) δ 13.37. Anal. Calcd for C₁₄H₁₄ClN₂O₄PS (372.76): C, 45.11; H, 3.79; N 7.52%. Found: C, 44.98; H, 3.82; N 7.51%.

Diethyl (8-nitro-4-oxo-4H-benzo[4,5]thiazolo[3,2-*a*]pyrimidin-3-yl)phosphonate (6e). (71%); yellow crystals; mp 125-127 °C, IR ν (cm⁻¹): 2984 (w), 1606 (m), 1525 (s), 1209 (s), 1016 (vs); ¹H NMR (250 MHz, CDCl₃) δ 9.31 (d, J 9.3 Hz, 1H, *H*-Ar), 8.67 (d, J 2.3 Hz, 1H, *H*-Ar), 8.58 (d, J 9.8 Hz, 1H, *H*-2), 8.45 (dd, J 9.3, 2.3 Hz, 1H, *H*-Ar), 4.45 – 4.15 (m, 4H, CH₂OP), 1.40 (t, J 7.1 Hz, 6H); ¹³C NMR (63 MHz, CDCl₃) δ 166.4 (s, C-Ar), 159.4 (d, J 11.0 Hz, C-3), 158.6 (d, J 12.8 Hz, C(O)), 146.1 (s, C-NO₂), 139.5 (s, C-Ar), 125.6 (s, C-Ar), 122.8 (s, CH-Ar), 120.6 (s, CH-Ar), 117.9 (s, CH-Ar), 110.0 (d, J 197.3 Hz, C-2), 63.0 (d, J 5.9 Hz, CH₂OP), 16.3 (d, J 6.4 Hz, CH₃CH₂OP); ³¹P NMR (101 MHz, CDCl₃) δ 12.96. Anal. Calcd for C₁₄H₁₄N₃O₆PS (383.31): C, 43.87; H, 3.68; N 10.96%. Found: C, 43.75; H, 3.72; N 10.92%.

General procedure for the synthesis of 3-substituted 4H-pyrimidobenzothiazol-4-ones 10a, d,e,i-l. To a solution of the corresponding phosphonate **6a-c** (1 mmol) and a catalytic amount of CuI (19 mg, 0.1 mmol) in THF (10 mL) a solution of Grignard reagent (5 mmol) was added dropwise, under an argon atmosphere at -78 °C. The solution was stirred for 24 h at rt. After this time the reaction mixture was quenched with H₂O (2 mL), acidified to pH ca. 1.5 with 10% aq HCl solution and extracted with CHCl₃ (3 × 10 mL). The organic extracts were washed with brine (10 mL) and dried over MgSO₄. Evaporation of the solvent gave the crude product which was purified by column chromatography (eluent: CHCl₃–MeOH, 99:1).

Diethyl (2-methyl-4-oxo-3,4-dihydro-2H-benzo[4,5]thiazolo[3,2-*a*]pyrimidin-3-yl)phosphonate (10a). (80%); yellow oil; IR ν (cm⁻¹): 2926 (w), 1638 (s), 1467 (m), 1252 (s), 1012 (vs); ¹H NMR (250 MHz, CDCl₃) δ 8.33 – 8.26 (m, 1H, major and minor, *H*-Ar), 7.34 – 7.16 (m, 3H, major and minor, *H*-Ar), 4.52 (ddd, J 14.9, 6.9, 1.1 Hz, 1H, major, *H*-2), 4.25 – 4.05 (m, 5H, major and minor, CH₂OP, minor, *H*-2), 3.30 (dd, J 24.2, 5.7 Hz, 1H, minor, *H*-3), 3.08 (dd, J 24.8, 1.1 Hz, 1H, major, *H*-3), 1.34 (t, J 7.0 Hz, 3H, major and minor, CH₃CH₂O), 1.31 (t, J 6.9 Hz, 3H, major and minor, CH₃), 1.24 (t, J 7.1 Hz, 3H, major and minor, CH₃CH₂O); ¹³C NMR (63 MHz, CDCl₃, major) δ 162.5 (d, J 5.1 Hz, C(O)), 153.8 (s, C-Ar), 135.2 (s, C-Ar), 126.1 (s, CH-Ar), 125.4 (s, CH-Ar), 122.4 (s, C-Ar), 121.3 (s, CH-Ar), 116.7 (s, CH-Ar), 63.1 (d, J 6.8 Hz, CH₂OP), 62.8 (d, J 6.6 Hz, CH₂OP), 52.0 (d, J 4.6 Hz, C-2), 46.5 (d, J 127.0 Hz, C-3), 20.5 (d, J 18.7 Hz, CH₃CH), 15.9 (d, J 6.1 Hz, CH₃CH₂OP); ³¹P NMR (101 MHz, CDCl₃) δ 19.93 (major), 19.43 (minor). Anal. Calcd for C₁₅H₁₉N₂O₄PS (354.36): C, 50.84; H, 5.40; N 7.91%. Found: C, 50.77; H, 5.42; N 7.95%.

Diethyl (2-butyl-4-oxo-3,4-dihydro-2H-benzo[4,5]thiazolo[3,2-*a*]pyrimidin-3-yl)phosphonate (10d). (75%); yellow oil; IR ν (cm⁻¹): 2956 (w), 1646 (s), 1464 (m), 1248 (s), 1016 (vs); ¹H NMR (250 MHz, CDCl₃) δ 8.29 – 8.22 (m, 1H, major and minor, *H*-Ar), 7.34 – 7.13 (m, 3H, major and minor, *H*-Ar), 4.42 – 4.27 (m, 2H, major and minor, *H*-2), 4.23 – 4.03 (m, 4H, major and minor, CH₂OP), 3.27 (dd, J 24.0, 5.5 Hz, 1H, minor, *H*-3), 3.10 (dd, J 25.1, 0.9 Hz, 1H, major, *H*-3), 1.78 – 1.58 (m, 1H, major and minor, CH₂), 1.56 – 1.26 (m, 5H, major and minor,

CH_2), 1.31 (t, J 7.1 Hz, 3H, major and minor, $\text{CH}_3\text{CH}_2\text{O}$), 1.24 (t, J 7.1 Hz, 3H, major and minor, $\text{CH}_3\text{CH}_2\text{O}$), 0.86 (t, J 7.1 Hz, 3H, major and minor, CH_3CH_2); ^{13}C NMR (63 MHz, CDCl_3 , major) δ 162.9 (d, J 5.2 Hz, $\text{C}(\text{O})$), 153.6 (s, C-Ar), 135.5 (s, C-Ar), 126.3 (s, CH-Ar), 125.7 (s, CH-Ar), 122.8 (s, C-Ar), 121.5 (s, CH-Ar), 117.0 (s, CH-Ar), 63.4 (d, J 6.8 Hz, CH_2OP), 63.1 (d, J 6.5 Hz, CH_2OP), 56.5 (d, J 4.7 Hz, C-2), 45.4 (d, J 126.9 Hz, C-3), 35.0 (d, J 17.2 Hz, CH_2CH), 27.7 (s, CH_2), 22.3 (s, CH_2), 16.2 (d, J 5.0 Hz, $\text{CH}_3\text{CH}_2\text{OP}$), 13.8 (s, CH_3); ^{31}P NMR (101 MHz, CDCl_3) δ 20.34 (major), 19.15 (minor). Anal. Calcd for $\text{C}_{18}\text{H}_{25}\text{N}_2\text{O}_4\text{PS}$ (396.44): C, 54.53; H, 6.36; N 7.07%. Found: C, 54.45; H, 6.40; N 7.01%.

Diethyl (4-oxo-2-phenyl-3,4-dihydro-2H-benzo[4,5]thiazolo[3,2-*a*]pyrimidin-3-yl)phosphonate (10e). (93%); yellow oil; IR $\nu(\text{cm}^{-1})$: 2982 (w), 1643 (s), 1463 (m), 1279 (s), 1015 (vs); ^1H NMR (250 MHz, CDCl_3) δ 8.29 – 8.24 (m, 1H, *H*-Ar), 7.34 – 7.13 (m, 8H, *H*-Ar), 5.60 (dd, J 16.4, 1.2 Hz, 1H, *H*-2), 4.28 – 4.13 (m, 4H, CH_2OP), 3.46 (dd, J 24.8, 1.2 Hz, 1H, *H*-3), 1.35 (t, J 7.1 Hz, 3H, $\text{CH}_3\text{CH}_2\text{O}$), 1.27 (t, J 7.1 Hz, 3H, $\text{CH}_3\text{CH}_2\text{O}$); ^{13}C NMR (63 MHz, CDCl_3) δ 162.2 (d, J 5.3 Hz, $\text{C}(\text{O})$), 155.8 (s, C-Ar), 139.4 (d, J 17.2 Hz, C-Ar), 135.5 (s, C-Ar), 129.0 (s, 2 x CH-Ar), 128.0 (s, CH-Ar), 126.4 (s, CH-Ar), 125.8 (s, CH-Ar), 125.8 (s, 2 x CH-Ar), 122.5 (s, C-Ar), 121.6 (s, CH-Ar), 117.1 (s, CH-Ar), 63.6 (d, J 6.8 Hz, CH_2OP), 63.3 (d, J 6.6 Hz, CH_2OP), 59.6 (d, J 3.8 Hz, C-2), 47.6 (d, J 124.9 Hz, C-3), 16.2 (d, J 6.2 Hz, $\text{CH}_3\text{CH}_2\text{OP}$); ^{31}P NMR (101 MHz, CDCl_3) δ 19.64. Anal. Calcd for $\text{C}_{20}\text{H}_{21}\text{N}_2\text{O}_4\text{PS}$ (416.43): C, 57.68; H, 5.08; N 6.73%. Found: C, 57.72; H, 5.14; N 6.75%.

Diethyl (2-butyl-8-methyl-4-oxo-3,4-dihydro-2H-benzo[4,5]thiazolo[3,2-*a*]pyrimidin-3-yl)phosphonate (10i). (79%); yellow oil; IR $\nu(\text{cm}^{-1})$: 2929 (w), 1647 (s), 1478 (m), 1296 (s), 1017 (vs); ^1H NMR (250 MHz, CDCl_3) δ 8.14 (d, J 8.4 Hz, 1H, major and minor, *H*-Ar), 7.11 (d, J 1.1 Hz, 1H, major and minor, *H*-Ar), 7.04 (dd, J 8.4, 1.1 Hz, 1H, major and minor, *H*-Ar), 4.44 – 4.26 (m, 2H, major and minor, *H*-2), 4.24 – 4.04 (m, 4H, major and minor, CH_2OP), 3.27 (dd, J 24.1, 5.5 Hz, 1H, minor, *H*-3), 3.10 (dd, J 25.1, 1.0 Hz, 1H, major, *H*-3), 2.35 (s, 3H, CH_3), 1.79 – 1.62 (m, 2H, major and minor, CH_2), 1.57 – 1.28 (m, 4H, major and minor, CH_2), 1.32 (t, J 7.1 Hz, 3H, major and minor, $\text{CH}_3\text{CH}_2\text{O}$), 1.23 (t, J 7.1 Hz, 3H, major and minor, $\text{CH}_3\text{CH}_2\text{O}$), 0.88 (t, J 7.1 Hz, 3H, major and minor, CH_3CH_2); ^{13}C NMR (63 MHz, CDCl_3 , major) δ 162.7 (d, J 5.2 Hz, $\text{C}(\text{O})$), 153.9 (s, C-Ar), 135.7 (s, C-Ar), 133.3 (s, C-Ar), 126.9 (s, CH-Ar), 122.6 (s, C-Ar), 121.9 (s, CH-Ar), 116.7 (s, CH-Ar), 63.4 (d, J 6.7 Hz, CH_2OP), 63.0 (d, J 6.7 Hz, CH_2OP), 56.5 (d, J 4.7 Hz, C-2), 45.4 (d, J 126.9 Hz, C-3), 35.0 (d, J 17.2 Hz, CH_2CH), 27.7 (s, CH_2), 22.3 (s, CH_2), 21.0 (s, CH_3), 16.2 (d, J 4.2 Hz, $\text{CH}_3\text{CH}_2\text{OP}$), 13.8 (s, CH_3); ^{31}P NMR (101 MHz, CDCl_3) δ 20.50 (major), 19.29 (minor). Anal. Calcd for $\text{C}_{19}\text{H}_{27}\text{N}_2\text{O}_4\text{PS}$ (410.47): C, 55.60; H, 6.63; N 6.82%. Found: C, 55.39; H, 6.68; N 6.87%.

Diethyl (8-methyl-4-oxo-2-phenyl-3,4-dihydro-2H-benzo[4,5]thiazolo[3,2-*a*]pyrimidin-3-yl)phosphonate (10j). (83%); yellow oil; IR $\nu(\text{cm}^{-1})$: 2982 (w), 1643 (s), 1478 (m), 1252 (s), 1014 (vs); ^1H NMR (250 MHz, CDCl_3) δ 8.13 (d, J 8.4 Hz, 1H, *H*-Ar), 7.38 – 7.20 (m, 5H, *H*-Ar), 7.16 (d, J 1.1 Hz, 1H, *H*-Ar), 7.05 (dd, J 8.4, 1.1 Hz, 1H, *H*-Ar), 5.58 (dd, J 16.4, 1.2 Hz, 1H, *H*-2), 4.28 – 4.12 (m, 4H, CH_2OP), 3.46 (dd, J 24.8, 1.2 Hz, 1H, *H*-3), 2.36 (s, 1H, CH_3), 1.35 (t, J 7.1 Hz, 3H, $\text{CH}_3\text{CH}_2\text{O}$), 1.27 (t, J 7.1 Hz, 3H, $\text{CH}_3\text{CH}_2\text{O}$); ^{13}C NMR (63 MHz, CDCl_3) δ 161.9 (d, J 5.1 Hz, $\text{C}(\text{O})$), 156.0 (s, C-Ar), 139.5 (d, J 17.5 Hz, C-Ar), 135.9 (s, C-Ar), 133.2 (s, C-Ar), 128.9 (s, 2 x CH-Ar), 127.9 (s, CH-Ar), 127.0 (s, CH-Ar), 125.8 (s, 2 x CH-Ar), 122.4 (s, C-Ar), 121.9 (s, CH-Ar), 116.8 (s, CH-Ar), 63.5 (d, J 6.7 Hz, CH_2OP), 63.3 (d, J 6.6 Hz, CH_2OP), 59.6 (d, J 3.6 Hz, C-2), 47.6 (d, J 124.8 Hz, C-3), 21.0 (s, CH_3), 16.2 (d, J 4.1 Hz, $\text{CH}_3\text{CH}_2\text{OP}$); ^{31}P NMR (101 MHz, CDCl_3) δ 19.77. Anal. Calcd for $\text{C}_{21}\text{H}_{23}\text{N}_2\text{O}_4\text{PS}$ (430.46): C, 58.59; H, 5.39; N 6.51%. Found: C, 58.52; H, 5.38; N 6.47%.

Diethyl (2-butyl-8-chloro-4-oxo-3,4-dihydro-2H-benzo[4,5]thiazolo[3,2-*a*]pyrimidin-3-yl)phosphonate (10k). (95%); yellow oil; IR $\nu(\text{cm}^{-1})$: 2930 (w), 1645 (s), 1480 (m), 1292 (s), 1015 (vs); ^1H NMR (250 MHz, CDCl_3) δ 8.20 (d, J 8.8 Hz, 1H, major and minor, *H*-Ar), 7.29 (d, J 1.1 Hz, 1H, major and minor, *H*-Ar), 7.21 (dd, J 8.8, 1.1 Hz, 1H, major and minor, *H*-Ar), 4.45 – 4.29 (m, 2H, major and minor, *H*-2), 4.24 – 4.04 (m, 4H, major and minor, CH_2OP), 3.27 (dd, J 24.0, 5.5 Hz, 1H, minor, *H*-3), 3.11 (dd, J 25.1, 1.0 Hz, 1H, major, *H*-3), 1.78 – 1.62 (m, 2H,

major and minor, CH_2), 1.56 – 1.28 (m, 4H, major and minor, CH_2), 1.33 (t, J 7.0 Hz, 3H, major and minor, $\text{CH}_3\text{CH}_2\text{O}$), 1.23 (t, J 7.1 Hz, 3H, major and minor, $\text{CH}_3\text{CH}_2\text{O}$), 0.88 (t, J 7.0 Hz, 3H, major and minor, CH_3CH_2); ^{13}C NMR (63 MHz, CDCl_3 , major) δ 162.8 (d, J 5.3 Hz, $\text{C}(\text{O})$), 152.9 (s, C-Ar), 135.0 (s, C-Ar), 131.0 (s, C-Ar), 126.4 (s, CH-Ar), 124.6 (s, C-Ar), 121.4 (s, CH-Ar), 117.7 (s, CH-Ar), 63.4 (d, J 6.7 Hz, CH_2OP), 63.1 (d, J 6.6 Hz, CH_2OP), 56.6 (d, J 4.8 Hz, C-2), 45.3 (d, J 126.7 Hz, C-3), 34.9 (d, J 17.0 Hz, CH_2CH), 27.6 (s, CH_2), 22.2 (s, CH_2), 16.2 (d, J 6.2 Hz, $\text{CH}_3\text{CH}_2\text{OP}$), 13.7 (s, CH_3); ^{31}P NMR (101 MHz, CDCl_3) δ 19.75 (major), 18.49 (minor). Anal. Calcd for $\text{C}_{18}\text{H}_{24}\text{ClN}_2\text{O}_4\text{PS}$ (430.88): C, 50.17; H, 5.61; N 6.50%. Found: C, 50.10; H, 5.64; N 6.52%.

Diethyl (8-chloro-4-oxo-2-phenyl-3,4-dihydro-2H-benzo[4,5]thiazolo[3,2-a]pyrimidin-3-yl)phosphonate (10l). (85%); yellow oil; IR $\nu(\text{cm}^{-1})$: 2980 (w), 1645 (s), 1461 (m), 1250 (m), 1012 (vs); ^1H NMR (250 MHz, CDCl_3) δ 8.18 (d, J 8.8 Hz, 1H, H -Ar), 7.38 – 7.18 (m, 7H, H -Ar), 5.60 (dd, J 16.4, 1.2 Hz, 1H, H -2), 4.27 – 4.11 (m, 4H, CH_2OP), 3.45 (dd, J 24.8, 1.2 Hz, 1H, H -3), 1.35 (t, J 7.1 Hz, 3H, $\text{CH}_3\text{CH}_2\text{O}$), 1.27 (t, J 7.1 Hz, 3H, $\text{CH}_3\text{CH}_2\text{O}$); ^{13}C NMR (63 MHz, CDCl_3) δ 162.1 (d, J 5.2 Hz, $\text{C}(\text{O})$), 155.1 (s, C-Ar), 139.1 (d, J 17.3 Hz, C-Ar), 134.0 (s, C-Ar), 131.2 (s, C-Ar), 129.0 (s, 2 x CH-Ar), 128.1 (s, CH-Ar), 126.5 (s, CH-Ar), 125.7 (s, 2 x CH-Ar), 124.4 (s, C-Ar), 121.5 (s, CH-Ar), 117.8 (s, CH-Ar), 63.64 (d, J 6.9 Hz, CH_2OP), 63.4 (d, J 6.6 Hz, CH_2OP), 59.7 (d, J 4.0 Hz, C-2), 47.5 (d, J 124.7 Hz, C-3), 16.2 (d, J 6.1 Hz, $\text{CH}_3\text{CH}_2\text{OP}$); ^{31}P NMR (101 MHz, CDCl_3) δ 19.07. Anal. Calcd for $\text{C}_{20}\text{H}_{20}\text{ClN}_2\text{O}_4\text{PS}$ (450.87): C, 53.28; H, 4.47; N 6.21%. Found: C, 53.25; H, 4.49; N 6.21%.

General procedure for the synthesis of 3-methylidene-4H-pyrimidobenzothiazol-4-ones 11a,d,e,i-l. To a solution of the corresponding 4H-pyrimidobenzothiazol-4-ones **10a,d,e,i-l** (0.5 mmol) in THF (5 mL), NaH (14 mg, 0.6 mmol) was added and the resulting mixture was stirred at rt for 30 min. Then, paraformaldehyde (75 mg, 2.5 mmol) was added in one portion. After 4 h, the reaction mixture was quenched with brine (10 mL) and extracted with CH_2Cl_2 (3 x 10 mL). The organic layer was dried over MgSO_4 and the solvent was evaporated. The crude product was purified by column chromatography (eluent: CH_2Cl_2).

2-Methyl-3-methylene-2,3-dihydro-4H-benzo[4,5]thiazolo[3,2-a]pyrimidin-4-one (11a). (51%); yellow oil; IR $\nu(\text{cm}^{-1})$: 2932 (w), 1642 (vs), 1455 (s), 1247 (m), 745 (vs); ^1H NMR (250 MHz, CDCl_3) δ 8.40 – 8.27 (m, 1H, H -Ar), 7.37 – 7.12 (m, 3H, H -Ar), 6.45 (dd, J 1.9, 0.7 Hz, 1H, $\text{CH}_2=\text{C}$), 5.69 (dd, J 2.0, 0.7 Hz, 1H, $\text{CH}_2=\text{C}$), 4.61 – 4.43 (m, 1H, H -2), 1.48 (t, J 6.9 Hz, 3H, CH_3); ^{13}C NMR (63 MHz, CDCl_3) δ 161.3 (s, $\text{C}(\text{O})$), 153.4 (s, C-Ar), 138.8 (s, C-Ar), 135.5 (s, C-Ar), 126.1 (s, CH-Ar), 125.6 (s, CH-Ar), 125.1 (s, CH_2), 123.4 (s, C-Ar), 121.4 (s, CH-Ar), 117.7 (s, CH-Ar), 56.3 (s, C-2), 22.2 (s, CH_3CH). Anal. Calcd for $\text{C}_{12}\text{H}_{10}\text{N}_2\text{OS}$ (230.29): C, 62.59; H, 4.38; N 12.16%. Found: C, 62.51; H, 4.42; N 12.19%.

2-Butyl-3-methylene-2,3-dihydro-4H-benzo[4,5]thiazolo[3,2-a]pyrimidin-4-one (11d). (34%); yellow oil; IR $\nu(\text{cm}^{-1})$: 2954 (w), 1648 (vs), 1454 (s), 1246 (m), 746 (vs); ^1H NMR (250 MHz, CDCl_3) δ 8.37 – 8.28 (m, 1H, H -Ar), 7.35 – 7.13 (m, 3H, H -Ar), 6.47 (dd, J 1.5, 1.0 Hz, 1H, $\text{CH}_2=\text{C}$), 5.64 (dd, J 1.6, 1.0 Hz, 1H, $\text{CH}_2=\text{C}$), 4.50 – 4.39 (m, 1H, H -2), 1.88 – 1.53 (m, 2H, CH_2), 1.50 – 1.22 (m, 4H, 2 x CH_2), 0.90 (t, J 6.9 Hz, 3H, CH_3); ^{13}C NMR (63 MHz, CDCl_3) δ 161.5 (s, $\text{C}(\text{O})$), 153.3 (s, C-Ar), 137.8 (s, C-Ar), 135.7 (s, C-Ar), 126.3 (s, CH-Ar), 126.0 (s, CH-Ar), 125.7 (s, CH_2), 123.6 (s, C-Ar), 121.5 (s, CH-Ar), 117.8 (s, CH-Ar), 61.5 (s, C-2), 36.2 (s, CH_2), 27.1 (s, CH_2), 22.4 (s, CH_2), 13.9 (s, CH_3). Anal. Calcd for $\text{C}_{15}\text{H}_{16}\text{N}_2\text{OS}$ (272.37): C, 66.15; H, 5.92; N 10.29%. Found: C, 66.02; H, 5.93; N 10.26%.

3-Methylene-2-phenyl-2,3-dihydro-4H-benzo[4,5]thiazolo[3,2-a]pyrimidin-4-one (11e). (69%); yellow oil; IR $\nu(\text{cm}^{-1})$: 2951 (w), 1640 (vs), 1451 (s), 1238 (m), 743 (vs); ^1H NMR (250 MHz, CDCl_3) δ 8.26 – 8.19 (m, 1H, H -Ar), 7.58 – 7.01 (m, 8H, H -Ar), 6.42 (d, J 2.0 Hz, 1H, $\text{CH}_2=\text{C}$), 5.44 (t, J 2.0 Hz, 1H, H -2), 5.40 (d, J 2.0 Hz, 1H, $\text{CH}_2=\text{C}$); ^{13}C NMR (63 MHz, CDCl_3) δ 161.0 (s, $\text{C}(\text{O})$), 155.1 (s, C-Ar), 140.0 (s, C-Ar), 137.5 (s, C-Ar), 135.5 (s, C-Ar), 128.6 (s, CH-Ar), 128.1 (s, 2 x CH-Ar), 127.7 (s, CH-Ar), 127.0 (s, 2 x CH-Ar), 126.3 (s, CH-Ar), 125.7 (s, CH_2), 121.5 (s,

C-Ar), 119.6 (s, CH-Ar), 117.7 (s, CH-Ar), 64.4 (s, C-2). Anal. Calcd for $C_{17}H_{12}N_2OS$ (292.36): C, 69.84; H, 4.14; N 9.58%. Found: C, 69.80; H, 4.15; N 9.61%.

2-Butyl-8-methyl-3-methylene-2,3-dihydro-4H-benzo[4,5]thiazolo[3,2-a]pyrimidin-4-one (11i). (76%); yellow oil; IR $\nu(\text{cm}^{-1})$: 2956 (w), 1645 (vs), 1454 (s), 1240 (m), 811 (vs); ^1H NMR (250 MHz, CDCl_3) δ 8.19 (d, J 8.4 Hz, 1H, *H*-Ar), 7.11 (d, J 1.1 Hz, 1H, *H*-Ar), 7.04 (dd, J 8.4, 1.1 Hz, 1H, *H*-Ar), 6.45 (d, J 1.2 Hz, 1H, $\text{CH}_2=\text{C}$), 5.62 (d, J 1.2 Hz, 1H, $\text{CH}_2=\text{C}$), 4.45 – 4.38 (m, 1H, *H*-2), 2.35 (s, CH_3), 1.83 – 1.55 (m, 2H, CH_2), 1.46 – 1.28 (m, 4H, 2 x CH_2), 0.90 (t, J 7.0 Hz, 3H, CH_3); ^{13}C NMR (63 MHz, CDCl_3) δ 161.4 (s, C(O)), 153.5 (s, C-Ar), 137.8 (s, C-Ar), 135.7 (s, CH-Ar), 133.3 (s, C-Ar), 126.9 (s, CH-Ar), 125.7 (s, CH_2), 123.4 (s, C-Ar), 121.9 (s, CH-Ar), 117.4 (s, CH-Ar), 61.5 (s, C-2), 36.2 (s, CH_2), 27.1 (s, CH_2), 22.4 (s, CH_2), 21.1 (s, CH_3), 13.9 (s, CH_3). Anal. Calcd for $C_{16}H_{18}N_2OS$ (286.39): C, 67.10; H, 6.34; N 9.78%. Found: C, 67.01; H, 6.36; N 9.75%.

8-Methyl-3-methylene-2-phenyl-2,3-dihydro-4H-benzo[4,5]thiazolo[3,2-a]pyrimidin-4-one (11j). (52%); yellow oil; IR $\nu(\text{cm}^{-1})$: 2924 (w), 1650 (vs), 1458 (s), 1256 (m), 811 (vs); ^1H NMR (250 MHz, CDCl_3) δ 8.20 (d, J 8.4 Hz, 1H, *H*-Ar), 7.40 – 7.28 (m, 5H, *H*-Ar), 7.16 – 7.11 (m, 1H, *H*-Ar), 7.11 – 7.03 (m, 1H, *H*-Ar), 6.51 (dd, J 2.1, 0.8 Hz, 1H, $\text{CH}_2=\text{C}$), 5.53 (t, J 2.1 Hz, 1H, *H*-2), 5.49 (dd, J 2.1, 0.8 Hz, 1H, $\text{CH}_2=\text{C}$), 2.36 (s, CH_3); ^{13}C NMR (63 MHz, CDCl_3) δ 161.0 (s, C(O)), 155.4 (s, C-Ar), 140.2 (s, C-Ar), 137.8 (s, C-Ar), 135.9 (s, CH-Ar), 133.3 (s, C-Ar), 128.7 (s, 2 x CH-Ar), 127.8 (s, CH-Ar), 127.8 (s, CH-Ar), 127.2 (s, 2 x CH-Ar), 127.0 (s, CH_2), 123.4 (s, C-Ar), 121.9 (s, C-Ar), 117.6 (s, CH-Ar), 64.6 (s, C-2), 21.1 (s, CH_3). Anal. Calcd for $C_{18}H_{14}N_2OS$ (306.38): C, 70.56; H, 4.61; N 9.14%. Found: C, 70.48; H, 4.64; N 9.16%.

2-Butyl-8-chloro-3-methylene-2,3-dihydro-4H-benzo[4,5]thiazolo[3,2-a]pyrimidin-4-one (11k). (78%); yellow oil; IR $\nu(\text{cm}^{-1})$: 2955 (w), 1648 (vs), 1506 (s), 1298 (m), 864 (vs); ^1H NMR (250 MHz, CDCl_3) δ 8.26 (d, J 8.8 Hz, 1H, *H*-Ar), 7.28 (d, J 2.2 Hz, 1H, *H*-Ar), 7.22 (dd, J 8.8, 2.2 Hz, 1H, *H*-Ar), 6.47 (d, J 1.3 Hz, 1H, $\text{CH}_2=\text{C}$), 5.66 (d, J 1.4 Hz, 1H, $\text{CH}_2=\text{C}$), 4.49 – 4.38 (m, 1H, *H*-2), 1.83 – 1.56 (m, 2H, CH_2), 1.45 – 1.28 (m, 4H, 2 x CH_2), 0.90 (t, J 7.0 Hz, 3H, CH_3).

8-Chloro-3-methylene-2-phenyl-2,3-dihydro-4H-benzo[4,5]thiazolo[3,2-a]pyrimidin-4-one (11l). (84%); yellow oil; IR $\nu(\text{cm}^{-1})$: 2917 (w), 1650 (vs), 1515 (s), 1181 (m), 751 (vs); ^1H NMR (250 MHz, CDCl_3) δ 8.19 (d, J 8.8 Hz, 1H, *H*-Ar), 7.37 – 7.19 (m, 6H, *H*-Ar), 7.19 – 7.14 (m, 1H, *H*-Ar), 6.46 (d, J 2.0 Hz, 1H, $\text{CH}_2=\text{C}$), 5.47 (t, J 2.0 Hz, 1H, *H*-2), 5.45 (d, J 2.0 Hz, 1H, $\text{CH}_2=\text{C}$).

General procedure for the preparation of diethyl (2-oxo-2H-benzothiazolopyrimidin-3-yl)phosphonates 9a,b,d. To a solution of ethyl 3-chloro-2-(diethoxyphosphoryl)acrylate **7** (10.0 mmol) in THF (50 mL) pyridine (5 mL) and (2.66 g, 10.0 mmol) 2-aminobenzotiazole **3a**, **b**, **e** were added and the mixture was stirred for 24 hours. After this time the reaction mixture was quenched with H_2O (2 mL), acidified to pH ca. 1.5 with 10% aq HCl solution and extracted with CHCl_3 (3 x 50 mL). The organic extracts were washed with brine (100 mL) and dried over MgSO_4 . Evaporation of the solvent gave the crude product, which was purified by column chromatography (eluent: CHCl_3 –MeOH, 97:3).

Diethyl (2-oxo-2H-benzo[4,5]thiazolo[3,2-a]pyrimidin-3-yl)phosphonate (9a). (96%); yellow crystals; mp 132–134 °C; IR $\nu(\text{cm}^{-1})$: 2987 (w), 1614 (s), 1486 (m), 1348 (m), 1218 (m), 981 (vs); ^1H NMR (250 MHz, CDCl_3) δ 8.87 (d, J 13.3 Hz, 1H, *H*-4), 7.73 – 7.45 (m, 4H, *H*-Ar), 4.42 – 4.17 (m, 4H, CH_2OP), 1.38 (t, J 7.1 Hz, 6H, $\text{CH}_3\text{CH}_2\text{O}$); ^{13}C NMR (63 MHz, CDCl_3) δ 164.6 (d, J 2.6 Hz, C(O)), 164.6 (s, C-Ar), 140.8 (d, J 17.3 Hz), 133.7 (s, C-Ar), 127.6 (s, CH-Ar), 127.1 (s, CH-Ar), 123.5 (s, C-Ar), 123.4 (s, CH-Ar), 111.8 (d, J 190.6 Hz, C-4), 111.7 (s, CH-Ar), 63.5 (d, J 6.1 Hz, CH_2OP), 16.2 (d, J 6.4 Hz, CH_3CH_2); ^{31}P NMR (101 MHz, CDCl_3) δ 12.32. Anal. Calcd for $C_{14}H_{15}N_2O_4P$ (338.32): C, 49.70; H, 4.47; N 8.28%. Found: C, 49.63; H, 4.51; N 8.25%. Crystal data: formula $C_{14}H_{15}N_2O_4P \cdot 0.5\text{H}_2\text{O}$, monoclinic, space group $P2_1/c$, $Z = 4$, cell constants $a = 14.5768(5)$ Å, $b = 14.1909(5)$ Å, $c = 8.1019(3)$ Å, $\beta = 105.862(2)^\circ$, $V = 1612.13(10)$ Å³. The integration of the data yielded a total of 13768 reflections to a θ

angle of 68.38°, of which 2928 were independent ($R_{\text{int}} = 6.62\%$) and 2707 were greater than $2\sigma(F^2)$. The final anisotropic full-matrix least-squares refinement on F^2 with 232 variables converged at $R_1 = 3.27\%$, for the observed data and $wR_2 = 9.30\%$ for all data. All non-solvent hydrogen atoms, were placed in calculated positions and refined isotropically using a riding model. The disordered hydrogen atoms of water molecule placed around the inversion center were refined using suitable DFIX and DANG restraints. The goodness-of-fit was 1.044. CCDC 1477145 contains the supplementary crystallographic data for this paper. They can be obtained free of charge from The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif

Diethyl (8-methyl-2-oxo-2H-benzo[4,5]thiazolo[3,2-*a*]pyrimidin-3-yl)phosphonate (9b). (58%); yellow crystals; mp 156-158 °C; IR $\nu(\text{cm}^{-1})$: 2983 (w), 1633 (vs), 1496 (s), 1275 (m), 1223 (s), 1051 (vs); ^1H NMR (250 MHz, CDCl_3) δ 8.87 (d, J 13.3 Hz, 1H, *H*-4), 7.53 (d, J 8.3 Hz, 1H, *H*-Ar), 7.49 (d, J 1.1 Hz, 1H, *H*-Ar), 7.36 (dd, J 8.3, 1.1 Hz, 1H, *H*-Ar), 4.38 – 4.19 (m, 4H, CH_2OP), 2.48 (s, 3H, CH_3), 1.37 (t, J 7.1 Hz, 6H, $\text{CH}_3\text{CH}_2\text{O}$); ^{13}C NMR (176 MHz, CDCl_3) δ 164.7 (d, J 5.2 Hz, $\text{C}(\text{O})$), 164.6 (s, *C*-Ar), 140.9 (d, J 17.5 Hz), 137.7 (s, *C*-Ar), 131.7 (s, *C*-Ar), 128.6 (s, *CH*-Ar), 123.6 (s, *C*-Ar), 123.4 (s, *CH*-Ar), 111.7 (d, J 190.5 Hz, *C*-4), 111.4 (s, *CH*-Ar), 63.6 (d, J 6.0 Hz, CH_2OP), 16.3 (d, J 6.4 Hz, CH_3CH_2); ^{31}P NMR (101 MHz, CDCl_3) δ 12.39. Anal. Calcd for $\text{C}_{15}\text{H}_{17}\text{N}_2\text{O}_4\text{PS}$ (352.34): C, 51.13; H, 4.86; N 7.95%. Found: C, 51.07; H, 4.90; N 8.01%.

Diethyl (8-methoxy-2-oxo-2H-benzo[4,5]thiazolo[3,2-*a*]pyrimidin-3-yl)phosphonate (9e). (76%); yellow crystals; mp 176-178 °C; IR $\nu(\text{cm}^{-1})$: 2983 (w), 1628 (vs), 1496 (vs), 1338 (s), 1237 (m), 1020 (vs); ^1H NMR (700 MHz, CDCl_3) δ 8.78 (d, J 13.2 Hz, 1H, *H*-4), 7.54 (d, J 9.1 Hz, 1H, *H*-Ar), 7.16 (d, J 2.5 Hz, 1H, *H*-Ar), 7.07 (dd, J 9.1, 2.5 Hz, 1H, *H*-Ar), 4.33 – 4.27 (m, 2H, CH_2OP), 4.26 – 4.20 (m, 2H, CH_2OP), 3.87 (s, 3H, CH_3), 1.35 (t, J 7.1 Hz, 6H, $\text{CH}_3\text{CH}_2\text{O}$); ^{13}C NMR (176 MHz, CDCl_3) δ 164.5 (d, J 5.1 Hz, $\text{C}(\text{O})$), 164.3 (s, *C*-Ar), 158.8 (s, *C*-OMe), 140.9 (d, J 17.7 Hz), 127.6 (s, *C*-Ar), 125.1 (s, *C*-Ar), 114.7 (s, *CH*-Ar), 112.6 (s, *CH*-Ar), 111.6 (d, J 190.1 Hz, *C*-4), 107.7 (s, *CH*-Ar), 63.6 (d, J 6.1 Hz, CH_2OP), 56.0 (s, CH_3O), 16.3 (d, J 6.4 Hz, CH_3CH_2); ^{31}P NMR (283 MHz, CDCl_3) δ 12.61. Anal. Calcd for $\text{C}_{15}\text{H}_{17}\text{N}_2\text{O}_5\text{PS}$ (368.34): C, 48.91; H, 4.65; N 7.61%. Found: C, 48.81; H, 4.64; N 7.57%.

General Procedure for the Synthesis of 4-substituted diethyl (2-oxo-3,4-dihydro-2H-benzothiazolopyrimidin-3-yl)phosphonates 12a-j,m. To a solution of the corresponding phosphonate **9a,b,e** (1 mmol) in THF (10 mL) a solution of Grignard reagent (5 mmol) was added dropwise, under an argon atmosphere at 0 °C. The solution was stirred for 24 h at rt. After this time the reaction mixture was quenched with H_2O (2 mL), acidified to pH ca. 1.5 with 10% aq HCl solution and extracted with CHCl_3 (3 $\times$ 10 mL). The organic extracts were washed with brine (10 mL) and dried over MgSO_4 . Evaporation of the solvent gave the crude product, which was purified by column chromatography (eluent: CHCl_3 –MeOH, 99:1).

Diethyl (4-methyl-2-oxo-3,4-dihydro-2H-benzo[4,5]thiazolo[3,2-*a*]pyrimidin-3-yl)phosphonate (12a). (73%); yellow crystals; mp 144-146 °C; IR $\nu(\text{cm}^{-1})$: 2983 (w), 1672 (s), 1505 (vs), 1345 (m), 1236 (m), 1012 (s); ^1H NMR (250 MHz, CDCl_3) δ 7.57 (d, J 7.7 Hz, 1H, *H*-Ar), 7.50 – 7.39 (m, 1H, *H*-Ar), 7.32 – 7.19 (m, 2H, *H*-Ar), 5.04 (dq, J 13.6, 6.8, 0.8 Hz, 1H, *H*-4), 4.23 – 4.08 (m, 2H, CH_2OP), 3.98 – 3.83 (m, 2H, CH_2OP), 3.15 (dd, J 23.6, 0.8 Hz, 1H, *H*-3), 1.47 (d, J 6.8 Hz, 3H, CH_3CH), 1.31 (t, J 7.1 Hz, 3H, $\text{CH}_3\text{CH}_2\text{O}$), 0.96 (t, J 7.1 Hz, 3H, $\text{CH}_3\text{CH}_2\text{O}$); ^{13}C NMR (176 MHz, CDCl_3) δ 171.7 (s, *C*-Ar), 168.1 (d, J 4.5 Hz, $\text{C}(\text{O})$), 137.3 (s, *C*-Ar), 127.4 (s, *CH*-Ar), 124.3 (s, *CH*-Ar), 123.5 (s, *C*-Ar), 122.8 (s, *CH*-Ar), 110.6 (s, *CH*-Ar), 63.5 (d, J 6.1 Hz, CH_2OP), 62.9 (d, J 6.1 Hz, CH_2OP), 49.5 (d, J 5.9 Hz, *C*-4), 45.4 (d, J 126.1 Hz, *C*-3), 18.9 (d, J 17.7 Hz, CH_3), 16.1 (d, J 6.3 Hz, CH_3CH_2), 15.8 (d, J 6.4 Hz, CH_3CH_2); ^{31}P NMR (283 MHz, CDCl_3) δ 19.37. Anal. Calcd for $\text{C}_{15}\text{H}_{19}\text{N}_2\text{O}_4\text{PS}$ (354.36): C, 50.84; H, 5.40; N 7.91%. Found: C, 50.84; H, 5.43; N 7.96%.

Diethyl (4-ethyl-2-oxo-3,4-dihydro-2H-benzo[4,5]thiazolo[3,2-*a*]pyrimidin-3-yl)phosphonate (12b). (68%); yellow crystals; mp 128-130 °C; IR $\nu(\text{cm}^{-1})$: 2961 (w), 1737 (m), 1497 (vs), 1348 (m), 1230 (m), 1013 (s); ^1H NMR

(700 MHz, CDCl₃) δ 7.55 (d, *J* 7.8 Hz, 1H, *H*-Ar), 7.42 (d, *J* 7.8 Hz, 1H, *H*-Ar), 7.24 (d, *J* 7.8 Hz, 1H, *H*-Ar), 7.20 (d, *J* 7.8 Hz, 1H, *H*-Ar), 4.82 (dt, *J* 14.0, 6.6 Hz, 1H, *H*-4), 4.19 – 4.12 (m, 2H, CH₂OP), 3.93 – 3.86 (m, 2H, CH₂OP), 3.24 (d, *J* 24.0 Hz, 1H, *H*-3), 1.91 – 1.79 (m, 2H, CH₃CH₂), 1.30 (d, *J* 7.0 Hz, 3H, CH₃CH₂O), 0.98 (t, *J* 7.4 Hz, 3H, CH₃CH), 0.94 (t, *J* 7.0 Hz, 3H, CH₃CH₂O); ¹³C NMR (176 MHz, CDCl₃) δ 172.8 (s, C-Ar), 168.4 (d, *J* 4.5 Hz, C(O)), 137.9 (s, C-Ar), 127.4 (s, CH-Ar), 124.2 (s, CH-Ar), 123.5 (s, C-Ar), 122.7 (s, CH-Ar), 111.1 (s, CH-Ar), 63.6 (d, *J* 6.6 Hz, CH₂OP), 62.9 (d, *J* 6.6 Hz, CH₂OP), 54.8 (d, *J* 5.9 Hz, C-4), 42.8 (d, *J* 127.0 Hz, C-3), 26.4 (d, *J* 16.4 Hz, CH₃CH₂), 16.2 (d, *J* 6.3 Hz, CH₃CH₂), 15.9 (d, *J* 6.5 Hz, CH₃CH₂), 9.6 (s, CH₃); ³¹P NMR (283 MHz, CDCl₃) δ 19.89. Anal. Calcd for C₁₆H₂₁N₂O₄PS (368.39): C, 52.17; H, 5.75; N 7.60%. Found: C, 52.17; H, 5.77; N 7.64%.

Diethyl (4-isopropyl-2-oxo-3,4-dihydro-2*H*-benzo[4,5]thiazolo[3,2-*a*]pyrimidin-3-yl)phosphonate (12c). (43%); yellow crystals; mp 152-154 °C; IR ν (cm⁻¹): 2967 (w), 1658 (m), 1493 (vs), 1367 (s), 1240 (m), 1016 (s); ¹H NMR (250 MHz, CDCl₃) δ 7.58 (d, *J* 7.9 Hz, 1H, *H*-Ar), 7.45 (d, *J* 7.9 Hz, 1H, *H*-Ar), 7.29 (d, *J* 7.9 Hz, 1H, *H*-Ar), 7.22 (d, *J* 7.9 Hz, 1H, *H*-Ar), 4.73 (dd, *J* 17.3, 5.3 Hz, 1H, *H*-4), 4.28 – 4.09 (m, 2H, CH₂OP), 4.04 – 3.82 (m, 2H, CH₂OP), 3.32 (d, *J* 24.9 Hz, 1H, *H*-3), 2.46 – 2.26 (m, 1H, (CH₃)₂CH), 1.33 (d, *J* 7.1 Hz, 3H, CH₃CH₂O), 1.03 (d, *J* 7.2 Hz, 3H, CH₃CH), 0.98 (d, *J* 6.8 Hz, 3H, CH₃CH), 0.95 (t, *J* 7.1 Hz, 3H, CH₃CH₂O); ¹³C NMR (176 MHz, CDCl₃) δ 172.9 (s, C-Ar), 168.4 (d, *J* 5.0 Hz, C(O)), 138.2 (s, C-Ar), 127.2 (s, CH-Ar), 124.1 (s, CH-Ar), 123.3 (s, C-Ar), 122.6 (s, CH-Ar), 111.1 (s, CH-Ar), 63.6 (d, *J* 6.6 Hz, CH₂OP), 62.9 (d, *J* 6.6 Hz, CH₂OP), 54.8 (d, *J* 5.9 Hz, C-4), 42.8 (d, *J* 127.0 Hz, C-3), 26.4 (d, *J* 16.4 Hz, CH₃CH), 16.2 (d, *J* 6.3 Hz, CH₃CH₂), 15.9 (d, *J* 6.5 Hz, CH₃CH₂), 9.6 (s, CH₃); ³¹P NMR (283 MHz, CDCl₃) δ 19.89. Anal. Calcd for C₁₇H₂₃N₂O₄PS (382.41): C, 53.39; H, 6.06; N 7.33%. Found: C, 53.30; H, 6.10; N 7.35%.

Diethyl (4-butyl-2-oxo-3,4-dihydro-2*H*-benzo[4,5]thiazolo[3,2-*a*]pyrimidin-3-yl)phosphonate (12d). (72%); yellow crystals; mp 122-124 °C; IR ν (cm⁻¹): 2959 (w), 1670 (m), 1497 (vs), 1348 (m), 1244 (m), 1016 (s); ¹H NMR (700 MHz, CDCl₃) δ 7.58 (d, *J* 7.9 Hz, 1H, *H*-Ar), 7.49 – 7.44 (m, 1H, *H*-Ar), 7.31 – 7.26 (m, 1H, *H*-Ar), 7.23 (d, *J* 8.2 Hz, 1H, *H*-Ar), 4.73 (dtd, *J* 14.6, 6.9, 0.5 Hz, 1H, *H*-4), 4.22 – 4.16 (m, 2H, CH₂OP), 3.95 – 3.90 (m, 2H, CH₂OP), 3.28 (dd, *J* 24.1, 0.5 Hz, 1H, *H*-3), 1.83 – 1.81 (m, 2H, CH₂), 1.44 – 1.35 (m, 4H, 2 x CH₂), 1.34 (d, *J* 7.0 Hz, 3H, CH₃CH₂O), 0.97 (d, *J* 7.0 Hz, 3H, CH₃CH₂O), 0.88 (d, *J* 7.1 Hz, 3H, CH₃CH); ¹³C NMR (176 MHz, CDCl₃) δ 171.9 (s, C-Ar), 168.1 (d, *J* 4.4 Hz, C(O)), 137.4 (s, C-Ar), 127.1 (s, CH-Ar), 123.9 (s, CH-Ar), 123.1 (s, C-Ar), 122.5 (s, CH-Ar), 110.7 (s, CH-Ar), 63.1 (d, *J* 6.5 Hz, CH₂OP), 62.6 (d, *J* 7.2 Hz, CH₂OP), 53.3 (d, *J* 6.7 Hz, C-4), 42.7 (d, *J* 126.8 Hz, C-3), 32.3 (d, *J* 16.0 Hz, CH₂CH), 26.6 (s, CH₂CH₂), 21.9 (s, CH₂CH₂), 15.8 (d, *J* 5.8 Hz, CH₃CH₂O), 15.9 (d, *J* 6.0 Hz, CH₃CH₂ O), 13.3 (s, CH₃CH₂); ³¹P NMR (283 MHz, CDCl₃) δ 19.53. Anal. Calcd for C₁₈H₂₅N₂O₄PS (396.44): C, 54.53; H, 6.36; N 7.07%. Found: C, 54.42; H, 6.37; N 7.04%.

Diethyl (2-oxo-4-phenyl-3,4-dihydro-2*H*-benzo[4,5]thiazolo[3,2-*a*]pyrimidin-3-yl)phosphonate (12e). (68%); yellow crystals; mp 175-177 °C; IR ν (cm⁻¹): 2980 (w), 1671 (m), 1494 (vs), 1354 (s), 1236 (s), 1023 (vs); ¹H NMR (700 MHz, CDCl₃) δ 7.62 – 7.56 (m, 1H, *H*-Ar), 7.38 – 7.29 (m, 4H, *H*-Ar), 7.28 – 7.18 (m, 3H, *H*-Ar), 7.10 – 7.04 (m, 1H, *H*-Ar), 5.95 (dd, *J* 17.2, 0.8 Hz, 1H, *H*-4), 4.29 – 4.15 (m, 2H, CH₂OP), 4.09 – 3.95 (m, 2H, CH₂OP), 3.40 (dd, *J* 23.4, 0.8 Hz, 1H, *H*-3), 1.36 (d, *J* 7.1 Hz, 3H, CH₃CH₂O), 1.06 (d, *J* 7.1 Hz, 3H, CH₃CH₂O); ¹³C NMR (176 MHz, CDCl₃) δ 173.0 (s, C-Ar), 167.4 (d, *J* 5.0 Hz, C(O)), 137.6 (s, C-Ar), 136.6 (d, *J* 15.9 Hz, C-Ar), 129.6 (s, 2 x CH-Ar), 129.1 (s, CH-Ar), 127.4 (s, CH-Ar), 125.2 (s, 2 x CH-Ar), 124.5 (s, CH-Ar), 123.1 (s, C-Ar), 122.6 (s, CH-Ar), 111.4 (s, CH-Ar), 63.7 (d, *J* 6.5 Hz, CH₂OP), 63.1 (d, *J* 7.1 Hz, CH₂OP), 56.7 (d, *J* 5.3 Hz, C-4), 47.0 (d, *J* 123.4 Hz, C-3), 16.1 (d, *J* 6.1 Hz, CH₃CH₂O), 15.9 (d, *J* 6.3 Hz, CH₃CH₂ O); ³¹P NMR (283 MHz, CDCl₃) δ 19.13. Anal. Calcd for C₂₀H₂₁N₂O₄PS (416.43): C, 57.69; H, 5.08; N 6.73%. Found: C, 57.59; H, 5.11; N 6.78%.

Diethyl (4,8-dimethyl-2-oxo-3,4-dihydro-2*H*-benzo[4,5]thiazolo[3,2-*a*]pyrimidin-3-yl)phosphonate (12f). (71%); yellow crystals; mp 152-154 °C; IR ν (cm⁻¹): 2983 (w), 1664 (m), 1498 (vs), 1357 (m), 1247 (m), 1019 (s); ¹H NMR (250 MHz, CDCl₃) δ 7.39 (s, 1H, *H*-Ar), 7.26 (d, *J* 8.2 Hz, 1H, *H*-Ar), 7.12 (d, *J* 8.2 Hz, 1H, *H*-Ar), 5.03

(dq, J 14.0, 6.9, 0.6 Hz, 1H, H -4), 4.22 – 4.15 (m, 2H, CH_2OP), 3.97 – 3.89 (m, 2H, CH_2OP), 3.15 (dd, J 23.6, 0.6 Hz, 1H, H -3), 2.43 (s, 3H, CH_3), 1.48 (dd, J 6.8, 1.5 Hz, 3H, CH_3CH), 1.34 (t, J 7.1 Hz, 3H, CH_3CH_2O), 1.00 (t, J 7.0 Hz, 3H, CH_3CH_2O); ^{13}C NMR (176 MHz, $CDCl_3$) δ 171.5 (s, C-Ar), 168.1 (d, J 4.6 Hz, C(O)), 135.1 (s, C-Ar), 134.4 (s, C-Ar), 128.3 (s, CH-Ar), 123.5 (s, C-Ar), 122.8 (s, CH-Ar), 110.3 (s, CH-Ar), 63.4 (d, J 6.5 Hz, CH_2OP), 62.7 (d, J 7.2 Hz, CH_2OP), 49.3 (d, J 6.0 Hz, C-4), 45.3 (d, J 126.9 Hz, C-3), 20.9 (s, CH_3), 18.9 (d, J 17.8 Hz, CH_3), 16.0 (d, J 6.2 Hz, CH_3CH_2), 15.8 (d, J 6.3 Hz, CH_3CH_2); ^{31}P NMR (283 MHz, $CDCl_3$) δ 19.13. Anal. Calcd for $C_{16}H_{21}N_2O_4PS$ (368.39): C, 52.17; H, 5.75; N 7.60%. Found: C, 52.11; H, 5.80; N 7.63%.

Diethyl (4-ethyl-8-methyl-2-oxo-3,4-dihydro-2H-benzo[4,5]thiazolo[3,2- α]pyrimidin-3-yl)phosphonate (12g). (85%); yellow crystals; mp 120-122 °C; IR ν (cm^{-1}): 2935 (w), 1661 (s), 1492 (vs), 1348 (s), 1238 (s), 1015 (vs); ^1H NMR (700 MHz, $CDCl_3$) δ 7.38 (s, 1H, H -Ar), 7.25 (d, J 8.3 Hz, 1H, H -Ar), 7.12 (d, J 8.3 Hz, 1H, H -Ar), 4.82 (dtd, J 15.4, 6.9, 0.6 Hz, 1H, H -4), 4.22 – 4.16 (m, 2H, CH_2OP), 3.95 – 3.89 (m, 2H, CH_2OP), 3.25 (dd, J 24.0, 0.6 Hz, 1H, H -3), 2.43 (s, 3H, CH_3), 1.91 – 1.82 (m, 2H, CH_3CH_2), 1.34 (d, J 7.1 Hz, 3H, CH_3CH_2O), 1.01 (t, J 7.5 Hz, 3H, CH_3CH), 0.98 (t, J 7.1 Hz, 3H, CH_3CH_2O); ^{13}C NMR (176 MHz, $CDCl_3$) δ 172.0 (s, C-Ar), 168.2 (d, J 6.5 Hz, C(O)), 135.6 (s, C-Ar), 134.3 (s, C-Ar), 128.2 (s, CH-Ar), 123.4 (s, C-Ar), 122.7 (s, CH-Ar), 110.7 (s, CH-Ar), 63.4 (d, J 6.5 Hz, CH_2OP), 62.7 (d, J 7.2 Hz, CH_2OP), 54.6 (d, J 3.6 Hz, C-4), 42.7 (d, J 126.7 Hz, C-3), 26.2 (d, J 16.5 Hz, CH_3CH_2), 20.9 (s, CH_3), 16.1 (d, J 6.2 Hz, CH_3CH_2), 15.8 (d, J 6.2 Hz, CH_3CH_2), 9.5 (s, CH_3); ^{31}P NMR (283 MHz, $CDCl_3$) δ 19.65. Anal. Calcd for $C_{17}H_{23}N_2O_4PS$ (382.41): C, 53.39; H, 6.06; N 7.33%. Found: C, 53.29; H, 6.07; N 7.35%.

Diethyl (4-isopropyl-8-methyl-2-oxo-3,4-dihydro-2H-benzo[4,5]thiazolo[3,2- α]pyrimidin-3-yl)phosphonate (12h). (78%); yellow crystals; mp 168-170 °C; IR ν (cm^{-1}): 2941 (w), 1663 (m), 1490 (vs), 1337 (m), 1237 (s), 1012 (vs); ^1H NMR (250 MHz, $CDCl_3$) δ 7.33 (s, 1H, H -Ar), 7.18 (d, J 8.4 Hz, 1H, H -Ar), 7.04 (d, J 8.4 Hz, 1H, H -Ar), 4.63 (ddd, J 17.3, 5.4, 0.7 Hz, 1H, H -4), 4.20 – 4.03 (m, 2H, CH_2OP), 3.93 – 3.77 (m, 2H, CH_2OP), 3.23 (dd, J 24.9, 0.7 Hz, 1H, H -3), 2.35 (s, 3H, CH_3), 2.32 – 2.22 (m, 1H, $(CH_3)_2CH$), 1.24 (d, J 7.1 Hz, 3H, CH_3CH_2O), 0.95 (d, J 7.0 Hz, 3H, CH_3CH), 0.91 (d, J 7.1 Hz, 3H, CH_3CH), 0.87 (t, J 7.0 Hz, 3H, CH_3CH_2O); ^{13}C NMR (176 MHz, $CDCl_3$) δ 172.6 (s, C-Ar), 168.7 (d, J 5.0 Hz, C(O)), 136.0 (s, C-Ar), 134.2 (s, C-Ar), 128.0 (s, CH-Ar), 123.2 (s, C-Ar), 122.6 (s, CH-Ar), 111.1 (s, CH-Ar), 63.3 (d, J 6.6 Hz, CH_2OP), 62.7 (d, J 7.0 Hz, CH_2OP), 58.6 (d, J 4.1 Hz, C-4), 39.7 (d, J 127.3 Hz, C-3), 31.6 (d, J 15.1 Hz, CH_3CH), 20.9 (s, CH_3), 18.6 (s, CH_3), 17.0 (s, CH_3), 16.0 (d, J 6.1 Hz, CH_3CH_2), 15.8 (d, J 6.4 Hz, CH_3CH_2); ^{31}P NMR (283 MHz, $CDCl_3$) δ 19.76. Anal. Calcd for $C_{18}H_{25}N_2O_4PS$ (396.44): C, 54.53; H, 6.36; N 7.07%. Found: C, 54.45; H, 6.39; N 7.12%.

Diethyl (4-butyl-8-methyl-2-oxo-3,4-dihydro-2H-benzo[4,5]thiazolo[3,2- α]pyrimidin-3-yl)phosphonate (12i). (74%); yellow crystals; mp 164-166 °C; IR ν (cm^{-1}): 2927 (w), 1661 (m), 1494 (vs), 1343 (m), 1242 (s), 1015 (s); ^1H NMR (700 MHz, $CDCl_3$) δ 7.38 (s, 1H, H -Ar), 7.25 (d, J 8.3 Hz, 1H, H -Ar), 7.11 (d, J 8.3 Hz, 1H, H -Ar), 4.86 (dtd, J 14.7, 6.9, 0.5 Hz, 1H, H -4), 4.22 – 4.15 (m, 2H, CH_2OP), 3.95 – 3.88 (m, 2H, CH_2OP), 3.26 (dd, J 24.2, 0.5 Hz, 1H, H -3), 2.43 (s, 3H, CH_3), 1.84 – 1.79 (m, 2H, CH_2), 1.44 – 1.35 (m, 4H, 2 x CH_2), 1.34 (d, J 7.3 Hz, 3H, CH_3CH_2O), 0.98 (d, J 7.1 Hz, 3H, CH_3CH_2O), 0.88 (d, J 7.1 Hz, 3H, CH_3CH); ^{13}C NMR (176 MHz, $CDCl_3$) δ 171.9 (s, C-Ar), 168.2 (d, J 4.5 Hz, C(O)), 135.6 (s, C-Ar), 134.3 (s, C-Ar), 128.2 (s, CH-Ar), 123.4 (s, C-Ar), 122.7 (s, CH-Ar), 110.6 (s, CH-Ar), 63.3 (d, J 6.7 Hz, CH_2OP), 62.7 (d, J 7.2 Hz, CH_2OP), 53.5 (d, J 5.5 Hz, C-4), 42.9 (d, J 126.7 Hz, C-3), 32.6 (d, J 16.0 Hz, CH_2CH_2), 26.9 (s, CH_2CH_2), 22.1 (s, CH_2CH_2), 20.9 (s, CH_3), 16.0 (d, J 6.2 Hz, CH_3CH_2O), 15.8 (d, J 5.8 Hz, CH_3CH_2O), 13.5 (s, CH_3CH_2); ^{31}P NMR (283 MHz, $CDCl_3$) δ 19.61. Anal. Calcd for $C_{19}H_{27}N_2O_4PS$ (410.47): C, 55.60; H, 6.63; N 6.82%. Found: C, 55.47; H, 6.66; N 6.86%.

Diethyl (8-methyl-2-oxo-4-phenyl-3,4-dihydro-2H-benzo[4,5]thiazolo[3,2- α]pyrimidin-3-yl)phosphonate (12j). (79%); yellow crystals; mp 180-182 °C; IR ν (cm^{-1}): 2982 (w), 1670 (m), 1499 (vs), 1351 (m), 1245 (m), 1017 (s); ^1H NMR (700 MHz, $CDCl_3$) δ 7.39 (s, 1H, H -Ar), 7.35 – 7.28 (m, 4H, H -Ar), 7.22 – 7.18 (m, 2H, H -Ar), 7.13 (d, J 8.4 Hz, 1H, H -Ar), 6.97 – 6.94 (m, 1H, H -Ar), 5.93 (dd, J 17.3, 0.7 Hz, 1H, H -4), 4.26 – 4.18 (m, 2H,

CH₂OP), 4.05 – 3.98 (m, 2H, CH₂OP), 3.39 (dd, *J* 23.4, 0.7 Hz, 1H, *H*-3), 2.38 (s, 3H, CH₃), 1.36 (d, *J* 7.3 Hz, 3H, CH₃CH₂O), 1.07 (d, *J* 7.1 Hz, 3H, CH₃CH₂O); ¹³C NMR (176 MHz, CDCl₃) δ 172.4 (s, C-Ar), 166.9 (d, *J* 4.5 Hz, C(O)), 136.2 (d, *J* 16.2 Hz, C-Ar), 134.9 (s, CH-Ar), 134.3 (s, CH-Ar), 129.1 (s, 2 x CH-Ar), 128.6 (s, C-Ar), 127.9 (s, C-Ar), 124.7 (s, CH-Ar), 122.5 (s, 2 x CH-Ar), 122.4 (s, CH-Ar), 110.6 (s, CH-Ar), 63.1 (d, *J* 6.6 Hz, CH₂OP), 62.6 (d, *J* 7.1 Hz, CH₂OP), 56.1 (d, *J* 7.1 Hz, C-4), 46.6 (d, *J* 123.1 Hz, C-3), 20.5 (s, CH₃), 15.7 (d, *J* 3.8 Hz, CH₃CH₂O), 15.5 (d, *J* 5.5 Hz, CH₃CH₂ O); ³¹P NMR (283 MHz, CDCl₃) δ 18.90. Anal. Calcd for C₂₁H₂₃N₂O₄PS (430.46): C, 58.60; H, 5.39; N 6.51%. Found: C, 58.43; H, 5.41; N 6.54%.

Diethyl (4-butyl-8-methoxy-2-oxo-3,4-dihydro-2H-benzo[4,5]thiazolo[3,2-*a*]pyrimidin-3-yl)phosphonate (12m). (89%); yellow crystals; mp 148-150 °C; IR ν(cm⁻¹): 2925 (w), 1658 (m), 1496 (vs), 1360 (m), 1238 (s), 1014 (s); ¹H NMR (700 MHz, CDCl₃) δ 7.13 (d, *J* 8.9 Hz, 1H, *H*-Ar), 7.10 (d, *J* 2.5 Hz, 1H, *H*-Ar), 7.01 (dd, *J* 8.9, 2.5 Hz, 1H, *H*-Ar), 4.84 (dtd, *J* 15.4, 6.9, 0.6 Hz, 1H, *H*-4), 4.22 – 4.15 (m, 2H, CH₂OP), 3.97 – 3.89 (m, 2H, CH₂OP), 3.85 (s, 3H, CH₃O), 3.25 (dd, *J* 24.1, 0.6 Hz, 1H, *H*-3), 1.85 – 1.79 (m, 2H, CH₂), 1.42 – 1.36 (m, 2H, CH₂), 1.34 (d, *J* 7.1 Hz, 3H, CH₃CH₂O), 1.33 – 1.28 (m, 2H, CH₂), 1.00 (d, *J* 7.1 Hz, 3H, CH₃CH₂O), 0.88 (d, *J* 7.1 Hz, 3H, CH₃CH); ¹³C NMR (176 MHz, CDCl₃) δ 171.3 (s, C-Ar), 167.7 (d, *J* 4.4 Hz, C(O)), 156.4 (s, C-Ar), 131.3 (s, CH-Ar), 124.4 (s, CH-Ar), 114.1 (s, CH-Ar), 111.4 (s, C-Ar), 107.8 (s, C-Ar), 62.9 (d, *J* 6.6 Hz, CH₂OP), 62.4 (d, *J* 7.3 Hz, CH₂OP), 55.5 (s, CH₃O), 53.3 (d, *J* 5.1 Hz, C-4), 42.7 (d, *J* 126.9 Hz, C-3), 32.3 (d, *J* 16.1 Hz, CH₂CH), 26.6 (s, CH₂CH₂), 21.8 (s, CH₂CH₂), 15.8 (d, *J* 5.8 Hz, CH₃CH₂O), 15.6 (d, *J* 6.0 Hz, CH₃CH₂ O), 13.3 (s, CH₃CH₂); ³¹P NMR (283 MHz, CDCl₃) δ 19.67. Anal. Calcd for C₁₉H₂₇N₂O₅PS (426.47): C, 53.51; H, 6.38; N 6.57%. Found: C, 53.38; H, 6.40; N 6.61%.

General procedure for the synthesis of 3-methylene-3,4-dihydro-2H-benzothiazolopyrimidin-2-one 13a-j,m. To a solution of the corresponding diethyl (2-oxo-3,4-dihydro-2H-benzothiazolopyrimidin-3-yl)phosphonate **12a-j,m** (0.5 mmol) in THF (5 mL), K₂CO₃ (138 mg, 1.0 mmol) was added and the resulting mixture was stirred at rt for 30 min. Then, paraformaldehyde (75 mg, 2.5 mmol) was added in one portion. After 24 h, the reaction mixture was quenched with brine (10 mL) and extracted with CH₂Cl₂ (3 × 10 mL). The organic layer was dried over MgSO₄ and the solvent was evaporated. The crude product was purified by column chromatography (eluent: Et₂O).

4-Methyl-3-methylene-3,4-dihydro-2H-benzo[4,5]thiazolo[3,2-*a*]pyrimidin-2-one (13a). (76%); yellow oil; IR ν(cm⁻¹): 2924 (w), 1666 (m), 1494 (vs), 1357 (m), 745 (s); ¹H NMR (250 MHz, CDCl₃) δ 7.63 – 7.55 (m, 1H, *H*-Ar), 7.51 – 7.41 (m, 1H, *H*-Ar), 7.35 – 7.27 (m, 1H, *H*-Ar), 7.24 – 7.16 (m, 1H, *H*-Ar), 6.38 (s, 1H, CH₂=C), 5.60 (s, 1H, CH₂=C), 5.21 (q, *J* 6.8 Hz, 1H, *H*-4), 1.56 (d, *J* 6.8 Hz, 3H, CH₃); ¹³C NMR (63 MHz, CDCl₃) δ 171.6 (s, C-Ar), 167.1 (s, C(O)), 137.3 (s, C=), 135.6 (s, C-Ar), 127.3 (s, CH-Ar), 124.3 (s, C-Ar), 124.2 (s, CH-Ar), 123.7 (s, CH-Ar), 122.8 (s, CH₂=), 110.8 (s, CH-Ar), 54.7 (s, C-2), 21.6 (s, CH₃). Anal. Calcd for C₁₂H₁₀N₂OS (230.29): C, 62.59; H, 4.38; N, 12.16%. Found: C, 62.45; H, 4.41; N, 12.19%.

4-Ethyl-3-methylene-3,4-dihydro-2H-benzo[4,5]thiazolo[3,2-*a*]pyrimidin-2-one (13b). (82%); yellow oil; IR ν(cm⁻¹): 2953 (w), 1635 (m), 1496 (vs), 1342 (m), 746 (s); ¹H NMR (700 MHz, CDCl₃) δ 7.58 (d, *J* 7.9 Hz, 1H, *H*-Ar), 7.45 (d, *J* 7.9 Hz, 1H, *H*-Ar), 7.28 (d, *J* 7.9 Hz, 1H, *H*-Ar), 7.16 (d, *J* 7.9 Hz, 1H, *H*-Ar), 6.43 (s, 1H, CH₂=C), 5.55 (s, 1H, CH₂=C), 4.97 (dd, *J* 8.5, 3.9 Hz, 1H, *H*-4), 1.92-1.87 (m, 2H, CH₃CH₂), 0.96 (t, *J* 7.4 Hz, 3H, CH₃); ¹³C NMR (176 MHz, CDCl₃) δ 172.2 (s, C-Ar), 167.6 (s, C(O)), 137.6 (s, C=), 135.5 (s, C-Ar), 127.2 (s, CH-Ar), 125.3 (s, CH-Ar), 124.2 (s, CH-Ar), 124.1 (s, C-Ar), 122.9 (s, CH₂=), 110.8 (s, CH-Ar), 60.4 (s, C-2), 27.2 (s, CH₃CH₂), 8.5 (s, CH₃CH₂). Anal. Calcd for C₁₃H₁₂N₂OS (244.31): C, 63.91; H, 4.95; N, 11.47%. Found: C, 63.90; H, 4.99; N, 11.50%.

4-Isopropyl-3-methylene-3,4-dihydro-2H-benzo[4,5]thiazolo[3,2-*a*]pyrimidin-2-one (13c). (32%); yellow oil; IR ν(cm⁻¹): 2954 (w), 1675 (s), 1491 (vs), 1337 (s), 1240 (m), 750 (m); ¹H NMR (700 MHz, CDCl₃) δ 7.58 (d, *J* 7.9 Hz, 1H, *H*-Ar), 7.43 (d, *J* 7.9 Hz, 1H, *H*-Ar), 7.28 (d, *J* 7.9 Hz, 1H, *H*-Ar), 7.12 (d, *J* 7.9 Hz, 1H, *H*-Ar), 6.47 (s, 1H, CH₂=C), 5.50 (s, 1H, CH₂=C), 4.89 (d, *J* 4.0 Hz, 1H, *H*-4), 2.39 (heptd, *J* 6.9, 4.0, 1H, CH(CH₃)₂), 1.03 (d, *J* 6.9 Hz,

3H, CH₃), 0.88 (d, *J* 6.9 Hz, 3H, CH₃); ¹³C NMR (176 MHz, CDCl₃) δ 172.5 (s, C-Ar), 168.2 (s, C(O)), 137.8 (s, C=), 131.1 (s, C-Ar), 127.1 (s, CH-Ar), 126.5 (s, CH-Ar), 124.2 (s, CH-Ar), 123.9 (s, C-Ar), 122.9 (s, CH₂=), 111.2 (s, CH-Ar), 64.4 (s, C-2), 31.9 (s, CH₃CH), 18.2 (s, CH₃CH), 16.0 (s, CH₃CH). Anal. Calcd for C₁₄H₁₄N₂OS (258.34): C, 65.09; H, 5.46; N, 10.84%. Found: C, 65.02; H, 5.48; N, 10.88%.

4-Butyl-3-methylene-3,4-dihydro-2H-benzo[4,5]thiazolo[3,2-*a*]pyrimidin-2-one (13d). (87%); yellow oil; IR ν(cm⁻¹): 2951 (w), 1669 (m), 1497 (vs), 1359 (s), 1242 (m), 751 (m); ¹H NMR (700 MHz, CDCl₃) δ 7.58 (d, *J* 7.9 Hz, 1H, *H*-Ar), 7.45 (d, *J* 7.9 Hz, 1H, *H*-Ar), 7.27 (d, *J* 7.9 Hz, 1H, *H*-Ar), 7.16 (d, *J* 7.9 Hz, 1H, *H*-Ar), 6.40 (s, 1H, CH₂=C), 5.53 (s, 1H, CH₂=C), 5.02 (dd, *J* 9.0, 3.7 Hz, 1H, *H*-4), 1.91 – 1.83 (m, 1H, CH₂), 1.82 – 1.75 (m, 1H, CH₂), 1.36 – 1.21 (m, 4H, 2 x CH₂), 0.85 (t, *J* 7.0 Hz, 3H, CH₃); ¹³C NMR (176 MHz, CDCl₃) δ 172.1 (s, C-Ar), 167.6 (s, C(O)), 137.6 (s, C=), 133.9 (s, C-Ar), 127.2 (s, CH-Ar), 125.0 (s, CH-Ar), 124.2 (s, CH-Ar), 124.0 (s, C-Ar), 122.9 (s, CH₂=), 110.8 (s, CH-Ar), 59.2 (s, C-2), 33.5 (s, CH₂), 25.9 (s, CH₂), 22.2 (s, CH₂), 13.7 (s, CH₃). Anal. Calcd for C₁₅H₁₆N₂OS (272.37): C, 66.15; H, 5.92; N, 10.29%. Found: C, 66.03; H, 5.96; N, 10.25%.

3-Methylene-4-phenyl-3,4-dihydro-2H-benzo[4,5]thiazolo[3,2-*a*]pyrimidin-2-one (13e). (61%); yellow oil; IR ν(cm⁻¹): 2996 (w), 1660 (m), 1486 (vs), 1358 (s), 1159 (m), 741 (s); ¹H NMR (700 MHz, CDCl₃) δ 7.56 (d, *J* 7.8 Hz, 1H, *H*-Ar), 7.34 – 7.29 (m, 2H, *H*-Ar), 7.29 – 7.25 (m, 2H, *H*-Ar), 7.24 – 7.20 (m, 3H, *H*-Ar), 6.98 (d, *J* 7.9 Hz, 1H, *H*-Ar), 6.40 (s, 1H, CH₂=C), 6.10 (s, 1H, CH₂=C), 5.72 (s, 1H, *H*-4); ¹³C NMR (176 MHz, CDCl₃) δ 172.8 (s, C-Ar), 166.6 (s, C(O)), 137.9 (s, C=), 137.7 (s, C-Ar), 134.7 (s, C-Ar), 129.7 (s, 2 x CH-Ar), 128.9 (s, CH-Ar), 127.2 (s, CH-Ar), 125.6 (s, CH-Ar), 125.4 (s, 2 x CH-Ar), 124.4 (s, CH-Ar), 123.6 (s, C-Ar), 122.7 (s, CH₂=), 111.7 (s, CH-Ar), 62.7 (s, C-2). Anal. Calcd for C₁₇H₁₂N₂OS (292.36): C, 69.84; H, 4.14; N, 9.58%. Found: C, 69.76; H, 4.12; N, 9.56%.

4,8-Dimethyl-3-methylene-3,4-dihydro-2H-benzo[4,5]thiazolo[3,2-*a*]pyrimidin-2-one (13f). (82%); yellow oil; IR ν(cm⁻¹): 2963 (w), 1665 (m), 1493 (vs), 1351 (s), 1158 (s), 746 (m); ¹H NMR (700 MHz, CDCl₃) δ 7.36 (s, 1H, *H*-Ar), 7.24 (d, *J* 8.2 Hz, 1H, *H*-Ar), 7.09 (d, *J* 8.2 Hz, 1H, *H*-Ar), 6.34 (s, 1H, CH₂=C), 5.57 (s, 1H, CH₂=C), 5.19 (q, *J* 6.8 Hz, 1H, *H*-4), 2.40 (s, 3H, CH₃), 1.52 (d, *J* 6.8 Hz, 3H, CH₃); ¹³C NMR (176 MHz, CDCl₃) δ 171.6 (s, C-Ar), 167.1 (s, C(O)), 135.8 (s, C=), 135.3 (s, C-Ar), 134.5 (s, C-Ar), 128.2 (s, CH-Ar), 124.1 (s, CH-Ar), 123.9 (s, C-Ar), 123.0 (s, CH₂=), 110.5 (s, CH-Ar), 54.9 (s, C-2), 21.7 (s, CH₃), 21.1 (s, CH₃). Anal. Calcd for C₁₃H₁₂N₂OS (244.31): C, 63.91; H, 4.95; N, 11.47%. Found: C, 63.83; H, 4.99; N, 11.46%.

4-Ethyl-8-methyl-3-methylene-3,4-dihydro-2H-benzo[4,5]thiazolo[3,2-*a*]pyrimidin-2-one (13g). (84%); yellow oil; IR ν(cm⁻¹): 2962 (w), 1658 (m), 1487 (vs), 1354 (s), 1167 (s), 780 (m); ¹H NMR (700 MHz, CDCl₃) δ 7.34 (s, 1H, *H*-Ar), 7.21 (d, *J* 8.3 Hz, 1H, *H*-Ar), 7.05 (d, *J* 8.3 Hz, 1H, *H*-Ar), 6.38 (s, 1H, CH₂=C), 5.52 (s, 1H, CH₂=C), 4.95 (dd, *J* 8.4, 4.0 Hz, 1H, *H*-4), 2.38 (s, 3H, CH₃), 1.90 – 1.78 (m, 2H, CH₃CH₂), 0.90 (t, *J* 7.4 Hz, 3H, CH₃); ¹³C NMR (176 MHz, CDCl₃) δ 171.9 (s, C-Ar), 167.5 (s, C(O)), 135.4 (s, C=), 134.4 (s, C-Ar), 133.6 (s, C-Ar), 128.1 (s, CH-Ar), 124.9 (s, CH-Ar), 123.8 (s, C-Ar), 122.9 (s, CH₂=), 110.6 (s, CH-Ar), 60.1 (s, C-2), 27.1 (s, CH₃CH₂), 21.0 (s, CH₃), 8.4 (s, CH₃CH₂). Anal. Calcd for C₁₄H₁₄N₂OS (258.34): C, 65.09; H, 5.46; N, 10.84%. Found: C, 64.94; H, 5.50; N, 10.87%.

4-Isopropyl-8-methyl-3-methylene-3,4-dihydro-2H-benzo[4,5]thiazolo[3,2-*a*]pyrimidin-2-one (13h). (39%); yellow oil; IR ν(cm⁻¹): 2958 (w), 1685 (m), 1489 (vs), 1347 (s), 1172 (m), 746 (m); ¹H NMR (700 MHz, CDCl₃) δ 7.38 (s, 1H, *H*-Ar), 7.22 (d, *J* 8.3 Hz, 1H, *H*-Ar), 7.01 (d, *J* 8.3 Hz, 1H, *H*-Ar), 6.46 (s, 1H, CH₂=C), 5.48 (s, 1H, CH₂=C), 4.85 (d, *J* 4.0 Hz, 1H, *H*-4), 2.42 (s, 3H, CH₃), 2.37 (heptd, *J* 6.9, 4.0, 1H, CH(CH₃)₂), 1.02 (d, *J* 6.9 Hz, 3H, CH₃), 0.86 (d, *J* 6.9 Hz, 3H, CH₃); ¹³C NMR (176 MHz, CDCl₃) δ 172.4 (s, C-Ar), 168.2 (s, C(O)), 135.7 (s, C=), 134.4 (s, C-Ar), 131.2 (s, C-Ar), 128.0 (s, CH-Ar), 126.3 (s, CH-Ar), 123.9 (s, C-Ar), 123.0 (s, CH₂=), 110.9 (s, CH-Ar), 64.4 (s, C-2), 31.9 (s, CH₃CH), 21.1 (s, CH₃), 18.1 (s, CH₃CH), 15.9 (s, CH₃CH). Anal. Calcd for C₁₅H₁₆N₂OS (272.37): C, 66.15; H, 5.92; N, 10.29%. Found: C, 66.01; H, 5.93; N, 10.33%.

4-Butyl-8-methyl-3-methylene-3,4-dihydro-2H-benzo[4,5]thiazolo[3,2-*a*]pyrimidin-2-one (13i). (87%); yellow oil; IR $\nu(\text{cm}^{-1})$: 2954 (w), 1665 (m), 1484 (vs), 1352 (s), 1152 (m), 746 (m); ^1H NMR (700 MHz, CDCl_3) δ 7.33 (s, 1H, *H*-Ar), 7.20 (d, *J* 8.3 Hz, 1H, *H*-Ar), 7.04 (d, *J* 8.3 Hz, 1H, *H*-Ar), 6.33 (s, 1H, $\text{CH}_2=\text{C}$), 5.50 (s, 1H, $\text{CH}_2=\text{C}$), 4.99 (dd, *J* 8.8, 3.8 Hz, 1H, *H*-4), 2.36 (s, 3H, CH_3), 1.83 – 1.77 (m, 1H, CH_2), 1.75 – 1.69 (m, 1H, CH_2), 1.30 – 1.15 (m, 4H, CH_2), 0.79 (t, *J* 7.0 Hz, 3H, CH_3); ^{13}C NMR (176 MHz, CDCl_3) δ 171.5 (s, C-Ar), 167.5 (s, C(O)), 135.3 (s, C=), 134.3 (s, C-Ar), 134.0 (s, C-Ar), 128.1 (s, CH-Ar), 124.7 (s, CH-Ar), 123.7 (s, C-Ar), 122.8 (s, $\text{CH}_2=$), 110.5 (s, CH-Ar), 59.0 (s, C-2), 33.5 (s, CH_2), 25.7 (s, CH_2), 22.0 (s, CH_2), 20.7 (s, CH_3), 13.6 (s, CH_3). Anal. Calcd for $\text{C}_{16}\text{H}_{18}\text{N}_2\text{OS}$ (286.39): C, 67.10; H, 6.34; N, 9.78%. Found: C, 67.01; H, 6.35; N, 9.76%.

8-Methyl-3-methylene-4-phenyl-3,4-dihydro-2H-benzo[4,5]thiazolo[3,2-*a*]pyrimidin-2-one (13j). (71%); yellow oil; IR $\nu(\text{cm}^{-1})$: 2972 (w), 1646 (m), 1490 (vs), 1352 (s), 742 (m); ^1H NMR (700 MHz, CDCl_3) δ 7.35 (s, 1H, *H*-Ar), 7.33 – 7.28 (m, 2H, *H*-Ar), 7.23 – 7.19 (m, 1H, *H*-Ar), 7.06 (d, *J* 8.3 Hz, 1H, *H*-Ar), 6.85 (d, *J* 8.3 Hz, 1H, *H*-Ar), 6.39 (s, 1H, $\text{CH}_2=\text{C}$), 6.06 (s, 1H, $\text{CH}_2=\text{C}$), 5.70 (s, 1H, *H*-4), 2.35 (s, 3H, CH_3); ^{13}C NMR (176 MHz, CDCl_3) δ 172.7 (s, C-Ar), 166.6 (s, C(O)), 137.9 (s, C=), 135.8 (s, C-Ar), 134.8 (s, C-Ar), 134.6 (s, C-Ar), 129.6 (s, 2 x CH-Ar), 128.9 (s, CH-Ar), 128.1 (s, CH-Ar), 125.5 (s, CH-Ar), 125.4 (s, 2 x CH-Ar), 123.6 (s, C-Ar), 122.8 (s, $\text{CH}_2=$), 111.4 (s, CH-Ar), 62.7 (s, C-2). Anal. Calcd for $\text{C}_{18}\text{H}_{14}\text{N}_2\text{OS}$ (306.38): C, 70.56; H, 4.61; N, 9.14%. Found: C, 70.52; H, 4.62; N, 9.15%.

4-Butyl-8-methoxy-3-methylene-3,4-dihydro-2H-benzo[4,5]thiazolo[3,2-*a*]pyrimidin-2-one (13m). (76%); yellow oil; IR $\nu(\text{cm}^{-1})$: 2953 (w), 1663 (m), 1481 (vs), 1355 (s), 1270 (s), 1150 (s), 808 (m); ^1H NMR (700 MHz, CDCl_3) δ 7.09 (d, *J* 2.5 Hz, 1H, *H*-Ar), 7.06 (d, *J* 8.9 Hz, 1H, *H*-Ar), 6.98 (dd, *J* 8.9, 2.5 Hz, 1H, *H*-Ar), 6.37 (s, 1H, $\text{CH}_2=\text{C}$), 5.50 (s, 1H, $\text{CH}_2=\text{C}$), 4.97 (dd, *J* 8.8, 3.8 Hz, 1H, *H*-4), 3.82 (s, 3H, CH_3O), 1.88 – 1.81 (m, 1H, CH_2), 1.78 – 1.72 (m, 1H, CH_2), 1.33 – 1.19 (m, 4H, CH_2), 0.83 (t, *J* 7.1 Hz, 3H, CH_3); ^{13}C NMR (176 MHz, CDCl_3) δ 171.6 (s, C-Ar), 167.4 (s, C(O)), 156.8 (s, C-Ar), 134.0 (s, C=), 131.4 (s, C-Ar), 125.2 (s, CH-Ar), 124.8 (s, C-Ar), 114.3 (s, C-Ar), 111.6 (s, $\text{CH}_2=$), 107.5 (s, CH-Ar), 59.3 (s, C-2), 55.9 (s, CH_3O), 33.6 (s, CH_2), 25.8 (s, CH_2), 22.1 (s, CH_2), 13.7 (s, CH_3). Anal. Calcd for $\text{C}_{16}\text{H}_{18}\text{N}_2\text{O}_2\text{S}$ (302.39): C, 63.55; H, 6.00; N, 9.26%. Found: C, 63.42; H, 6.04; N, 9.30%.

Acknowledgements

This work was financially supported by the National Science Centre of Poland (project DEC-2012/07/B/ST5/02006).

References

1. Vitaku, E.; Smith, D. T.; Njardarson, J. T. *J. Med. Chem.* **2014**, *57*, 10257-10274.
<http://dx.doi.org/10.1021/jm501100b>
2. Harutyunyan, A. A.; Panosyan, G. A.; Chishmarityan, S. G.; Tamazyan, R. A.; Aivazyan, A. G.; Paronikyan, R. V.; Stepanyan, H. M.; Sukasyan, R. S.; Grigoryan, A. S. *Russ. J. Org. Chem.* **2015**, *51*, 711-714.
<http://dx.doi.org/10.1134/S107042801505022X>
3. Hilal, H. S.; Ali-Shtayeh, M. S.; Arafat, R.; Al-Tel, T.; Voelter, W.; Barakat, A. *Eur. J. Med. Chem.* **2006**, *41*, 1017-1024.
<http://dx.doi.org/10.1016/j.ejmech.2006.03.025>
4. Kumar, G.; Sharma, P. K.; Sharma, S.; Singh, S. *J. Chem. Pharm. Res.* **2015**, *7*, 710-714.
5. Richardson, A.; McCarty, F. J. *J. Med. Chem.* **1972**, *15*, 1203-1206.
<http://dx.doi.org/10.1021/jm00282a001>

6. Wade, J. J.; Toso, C. B.; Matson, Ch. J.; Stelzer, V. L. *J. Med. Chem.* **1983**, 26, 608-611.
<http://dx.doi.org/10.1021/jm00358a031>
7. Bartovic, A.; Ilavsky, D.; Simo, O.; Zalibera, L.; Belicova, A.; Seman, M. *Collect. Czech. Chem. Commun.* **1995**, 60, 583-593.
<http://dx.doi.org/10.1135/cccc19950583>
8. Ahmad, N. M.; Jones, K. *Tetrahedron Lett.* **2010**, 3264-3265.
9. Prasad, P. R.; Shinde, S. D.; Waghmare, G. S.; Naik, V. L.; Bhuvaneswari, K.; Kuberkar, S. V. *J. Chem. Pharm. Res.* **2011**, 3, 20-27.
10. Prasad, P. R.; Bhuvaneswari, K.; Kumar, K. P.; Rajani, K.; Kuberkar, S. V. *J. Chem. Pharm. Res.* **2012**, 4, 1606-1611.
11. Refat, H. M.; Fadda, A. A. *Heterocycles* **2015**, 91, 1212-1226.
<http://dx.doi.org/10.3987/COM-15-13209>
12. Chadegani, C.; Darviche, D.; Balalaie, B. *Int. J. Org. Chem.* **2012**, 2, 31-37.
<http://dx.doi.org/10.4236/ijoc.2012.21006>
13. Wahe, H.; Mbafor, J. T.; Nkengfack, A. E.; Fomum, Z. T.; Cherkasov, R. A.; Sterner, O.; Doepp, D. *Arkivoc*, **2003**, xv, 107-114.
14. Gabr, M. T.; El-Gohary, N. S.; El-Bendary, E. R.; El-Kerdawy, M. M. *Med. Chem. Res.* **2015**, 24, 860-878.
<http://dx.doi.org/10.1007/s00044-014-1114-x>
15. Gabr, M. T.; El-Gohary, N. S.; El-Bendary, E. R.; El-Kerdawy, M. M. *Eur. J. Med. Chem.* **2014**, 85, 576-592.
<http://dx.doi.org/10.1016/j.ejmech.2014.07.097>
16. Eriskin, S.; Sener, N.; Yavuz, S.; Sener, I. *Med. Chem. Res.* **2014**, 23, 3733-3743.
<http://dx.doi.org/10.1007/s00044-014-0962-8>
17. Satyanarayana, S.; Kumar, K. P.; Reddy, P. L.; Narender, R.; Narasimhulu, G. *Tetrahedron Lett.* **2013**, 54, 4892-4895.
<http://dx.doi.org/10.1016/j.tetlet.2013.06.138>
18. Kitson, R. R. A.; Millemaggi, A.; Taylor, R. J. K. *Angew. Chem. Int. Ed.* **2009**, 48, 9426-9452.
<http://dx.doi.org/10.1002/anie.200903108>
19. Albrecht, A.; Albrecht, Ł.; Janecki, T. *Eur. J. Org. Chem.* **2011**, 15, 2747-2766.
<http://dx.doi.org/10.1002/ejoc.201001486>
20. Pięta, M.; Kędzia, J.; Janecka, A.; Pomorska, D. K.; Różalski, M.; Krajewska, U.; Janecki, T. *RSC Adv.* **2015**, 5, 78324-78335 and references cited therein.
<http://dx.doi.org/10.1039/C5RA16673J>
21. Modranka, J.; Janecki, T. *Tetrahedron* **2011**, 67, 9595-9601.
<http://dx.doi.org/10.1016/j.tet.2011.09.139>
22. Pietrzak A., Modranka J., Wojciechowski J., Janecki T.; Wolf W. M., *The Cambridge Structural Database*, CCDC 1478184, 2016.
23. Smith, M. B.; In March's Advanced Organic Chemistry, 7th Edition; John Wiley & Sons, Inc., Hoboken, New Jersey, 2013; p. 867.
24. Janecki, T.; Wąsek, T.; Różalski, M.; Krajewska, U.; Studzian, K.; Janecka, A. *Bioorg. Med. Chem. Lett.* **2006**, 16, 1430-1433.
<http://dx.doi.org/10.1016/j.bmcl.2005.11.032>
25. Janecki, T.; Wąsek, T. *Tetrahedron* **2004**, 60, 1049-1055.
<http://dx.doi.org/10.1016/j.tet.2003.11.083>

26. Modranka, J.; Albrecht, A.; Janecki, T. *Synlett* **2010**, 2867-2870.
27. Groom C. R.; Bruno I. J.; Lightfoot M. P.; Ward S. C. *Acta Cryst.* **2016**. *B72*, 171-179.
28. Bruker (2014). *APEX2*. Bruker–Nonius AXS Inc., Madison, Wisconsin, USA.